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The HIV-1 retrovirus has the ability to infect both dividing and non-dividing cells of 
its human host. In order to gain access into the nucleus, the viral nucleoprotein pre-
integration complex (PIC) requires carrier molecules for its transport through the 
nuclear pore. Following integration of the viral DNA into the host genome, regulatory 
proteins such as HIV Tat also require import into the nucleus to perform their 
functions. It has been suggested that members of the Karyopherin superfamily of 
nuclear transporters may aid in the transport of both PIC and regulatory viral proteins. 
The exact viral determinants that direct nuclear import, as well as which Importins are 
involved in their import remains very controversial in HIV research to date.  
 
In this study, the role of the Importin, Karyopherin β1 (Kpnβ1), in the nuclear import 
of the HIV-1 proteins Tat, Viral Protein R and Integrase was investigated. To 
determine its importance in the nuclear import of HIV proteins, Kpnβ1 was inhibited 
using siRNA and a small molecule inhibitor, c43. Tat transactivation as an indicator 
of Tat nuclear localisation was then assayed using the HIV LTR promoter, containing 
a Tat responsive element, fused to the luciferase reporter gene.  In addition, the 
localisation of the recombinant HIV-1 proteins after Kpnβ1 knockdown was also 
determined via fluorescence microscopy and Western blot analysis of nuclear and 
cytoplasmic protein fractions. Our data show that Tat transactivation capability was 
significantly reduced after inhibiting Kpnβ1 using siRNA. The same result was found 
when Kpnβ1 was inhibited with a previously undescribed inhibitor under 
investigation in our laboratory, c43. Fluorescent microscopy analysis of GFP-Tat 
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showed marginal cytoplasmic accumulation following Kpnβ1 knockdown in HeLa 
cells. Analysis of the PIC proteins GFP-Vpr and GFP-IN showed no effect on GFP-
Vpr localisation following Kpnβ1 inhibition, while a significant decrease in the ratio 
of nuclear/cytoplasmic fluorescent intensity for GFP-IN was observed. To confirm the 
change in GFP-IN localisation, we performed Western blot analysis on nuclear and 
cytoplasmic protein fractions. We saw a significant decrease in the nuclear GFP-IN 
protein levels. Together, our results show that while HIV Tat transactivation is 
decreased when Kpnβ1 is inhibited in TZM-bl cells, its subcellular localisation is 
partially affected in HeLa cells. We observed no effect on GFP-Vpr localisation, 
while IN localisation was significantly decreased in the nucleus via fluorescent 
microscopy and Western blot analysis, following Kpnβ1 knockdown. These 
preliminary findings suggest Kpnβ1 is involved in the nuclear import of the HIV 
proteins Tat and Integrase. The literature describes various other nuclear transporters 
shown to import these proteins, suggesting the virus has evolved in flexibility and 




CHAPTER ONE:  
INTRODUCTION 
 
1.1 The Human Immunodeficiency Virus (HIV) 
 
1.1.1 Epidemiology of HIV 
 
HIV was first isolated in 1984 and determined to be the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS). AIDS is a disease characterised by a 
compromised immune system that if attacked by an opportunistic infection, can lead 
to death (1, 2).  
 
According to the World Health Organisation, 34 million people were living with HIV 
in 2011, with 2.5 million new infections and 1.7 million deaths that year alone (3). 
HIV is therefore a global health threat, with the highest percentage of infected people 










In 2011, 5.6 million people living in South Africa were infected with HIV, accounting 
for 16% of the global disease burden. Unprotected sex with multiple partners has been 
described as the highest risk factor in this region (3). With the introduction of Highly 
Active Antiretrovirals (HAART), a combination of 3-5 drugs that target various 
stages of the HIV life cycle, and prevention strategies, South Africa has reduced its 
new infections by 41% from 2001 to 2011(4).  
 
Although progress is being made with the introduction of HAART, there is currently 
no widely available cure for AIDS. The current medications prevent the virus from 
replicating and therefore allow for an extended patient lifespan. As can be seen from 
figure 1.2, life expectancy has increased drastically since the introduction of highly 
active antiretroviral therapy (HAART) (Figure 1.2) (5). 
 
Figure 1.1. Global HIV Prevalence for 2012.  HIV is most prevalent in Sub-Saharan Africa and is 







 HAART targets many stages of the viral life cycle to effectively reduce the 
circulating viral load to undetectable levels. This combination therapy has reduced 
HIV infection from a deadly disease into a manageable, chronic condition (6). 
However, the virus persists in the body due to its ability to hide in viral reservoirs 
such as resting CD4+ T cells, leading to viral rebound following interruption of 
therapy (7, 8).  
 
Traditionally, HIV drugs have been targeted at viral proteins. The most common 
being Reverse Transcriptase inhibitors (zidovudine, didanosine, zalcitabine, 
stavudine, lamivudine, abacavir, emtricitabine and tenofovir, nevirapine, delavirdine, 
efavirenz and Etravirine), Protease inhibitors (saquinavir, ritonavir, indinavir, 
nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir) 
Figure 1.2. The annual number of people dying from AIDS-related causes globally compared to a 
scenario of no antiretroviral therapy. The graph spans 1996-2012. Taken from (162). 
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and recently the Integrase inhibitor (raltegravir) (9). However there are high mutation 
rates associated with viral proteins due to the lack of a proofreading function of the 
HIV-1 Reverse Transcriptase enzyme (10, 11). This has led to host factors are now 
becoming increasingly more viable candidates. Host proteins represent a much wider 
pool of possible targets, whereas the viral genome only encodes 15 proteins (12, 13).  
 
A prime example of a host protein being an excellent target is the CCR5 co-receptor. 
In order for HIV to enter target cells, it must bind either CCR5 or CXCR4 co-
receptors. In February 2007, a patient received complete stem cell transplantation 
with cells that contained a 32 base pair deletion in both alleles of the CCR5 gene, 
termed CCR5Δ32/Δ32. These cells possess non-functional CCR5 receptors that 
resulted in viral replication ceasing despite discontinuation of antiretroviral therapy 
(14).  No evidence of HIV replication has been observed in the patient in up to 5 years 
of follow up, in the absence of combination antiretroviral therapy (15). Although 
promising, the cost of the procedure results in it not being a viable ‘cure’ for the 
millions of poverty stricken patients.  
 
The best hope of eradicating the virus permanently is a prophylactic vaccine. 
However, the variability in the viral epitopes has resulted in difficulty with vaccine 
development. The HIV virus is highly diverse and dynamic, mainly due to the high  
mutation rates (16).  
 
There are two main types of HIV worldwide, HIV type 1(HIV-1) and HIV type 2 
(HIV-2) that were transferred from Simian Immunodeficiency Viruses (SIV) hosted 
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by chimpanzees or sooty mangabeys, respectively. HIV-1 will be the main focus of 
this dissertation as it is the cause of the HIV/AIDS pandemic in humans.  
 
Within HIV-1 there are three distinct groups; M, for Major, O or outlier and N for 
non-M, non-O. Group M is responsible for 98% of all HIV-1 infections worldwide 
(17). Even within group M, there are subgroups termed clades (A-K), as well as 
circulating recombinant forms (CRF) that occur when more than one virus subtype is 




Figure 1.3. A Phylogenetic tree analysis of Group M, N and O as well as subtypes and circulating 




To elicit broadly neutralising antibodies that can detect all these diverse phenotypes 
from a single vaccine will be a great challenge for HIV researchers. The answer will 
help not only to eradicate HIV but also other viruses that evolve at a similarly rapid 
rate.  
 
1.1.2 The HIV-1 Viral Genome and Life Cycle  
 
HIV belongs to the lentivirus subfamily of the retroviridae family of viruses, 
characterised by their RNA genomes and reverse transcription capability. These 
viruses differ from the oncovirus subfamily by possessing the ability to infect non-
dividing cells such as resting T cells and macrophages (18, 19). These non-dividing 
cells then act as viral reservoirs, evading the immune system and leading to 
recurrence of infection if HAART is discontinued. HIV is described as a ‘budding 
virus’ whose progeny are encapsulated by the host cell membrane and literally ‘bud 
off’ to infect susceptible cells. The viral life cycle consists of a series of steps that 
lead to integration into the host genome, enabling another round of replication and 
infection of fresh cells. The genome of HIV-1 encodes only 15 proteins, forcing the 
virus to exploit many host proteins for successful replication (20). The various stages 






Figure 1.5: Diagram showing (A) The structure and organisation of the HIV-1 virion, (B) The 
contents of the preintegration complex (PIC) and its requirement to be imported through the NPC. 
Taken from (21) 
 
The HIV-1 genome consists of the reading frames gag, pol and env (Figure 1.4). 
These are responsible for producing the viral core, Reverse Transcriptase, Integrase 
and Protease enzymes and the surface Envelope, respectively. The virus also encodes 
the regulatory genes tat and rev and the auxiliary genes nef, vif, vpr, vpx and vpu(21).  
The HIV-1 virus particle consists of an outer lipid membrane containing membrane 
glycoproteins and an inner cone-shaped core containing the viral RNA genome as 










Figure 1.4: Schematic outlining the organisation of the HIV-1 genome. The genome is made of three large open-
reading frames that express structural (Gag), enzymatic (Pol) and envelope (Env) proteins, surrounded by terminal 
repeated sequences LTR (Long Terminal Repeat). The genome also encodes regulatory (Tat and Rev) and auxiliary 




Successful infection requires overcoming various obstacles in order to integrate the 
viral genome into the host chromosome. There are various known steps that lead to 
productive viral infection and each HIV protein is responsible for different steps in 
the life cycle (Figure 1.6).  
 
Firstly, the virus must enter the cell, crossing the cell membrane. It achieves this 
through a series of steps that ultimately lead to fusion of the viral and cellular 
membranes and the emptying of the viral contents into the cell. The target cells of 
HIV contain a cell surface receptor, named cluster of differentiation 4 (CD4), 
previously termed T4, that was discovered in 1986 to be present on the surface of 
cells of the immune system and the brain (24). This group also showed that after T4 
receptor: HIV gp120 (encoded by the env gene) interaction, the virus enters the cell 
via receptor mediated endocytosis.  However, only later did it become clear that 
additional binding to a chemokine co- receptor, either CCR5 or CXCR4 depending on 
the strain and cell type, was necessary for cellular entry. Also, binding of CD4 to 
gp120 induces binding to CCR5 via a conformational change in the protein (25).  
 
After endocytosis into the cell, the virus sheds the capsid layer, releasing the viral 
genome, along with other proteins required for the journey into the nucleus. It has 
long been thought that this uncoating process occurs directly after entry into the cell, 
but recent evidence suggests it occurs closer to the nuclear membrane and that Capsid 
(CA) plays a pivotal role in various subsequent steps (reviewed in 25).  
 
After shedding, the viral RNA is reverse transcribed by the Reverse Transcriptase 
enzyme into double stranded cDNA that forms a high molecular weight nucleoprotein 
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complex with other viral proteins present in the core. This complex is then targeted to 
the nucleus and has been named the pre-integration complex (PIC) (27) (figure 1.5B). 
Tracking of virus particles in live cells with the green fluorescent protein (GFP) tag 
has shown the PIC to make use of the microtubule network to migrate towards the 
nuclear membrane (Figure 1.6) (28). The HIV-1 Capsid(CA) protein is the viral 
determinant that interacts with the microtubule network to transport the PIC towards 
the nucleus (29). Within 4-6 hours of infection, the viral DNA is imported into the 
nucleus through active transport mechanisms (30, 31). These import mechanisms 
form the context of the focus of this dissertation. There is contention within the 
literature regarding the exact PIC proteins necessary for mediating import through the 
nuclear pore complexes as well as which host proteins are involved.  
 
 
Figure 1.6: Diagram depicting transport of the HIV virion components from the extracellular space to the nucleus, 




The nuclear membrane forms a physical barrier between the contents of the nucleus 
and the cytoplasm. In order for the viral PIC to traverse this barrier, it needs to 
interact with the nuclear pore complexes (NPCs) that stud the nuclear membrane. 
A NPC is a 125 MDa complex composed of multiple proteins called nucleoporins that 
form a channel that allows for the selective passage of certain molecules across the 
nuclear membrane (32). The NPC allows ions and small proteins (<40kDa) to travel 
through this channel, while larger proteins require active, receptor mediated transport. 
The direction of cargo transport through the NPC is governed by a conserved signal in 
the cargo. A nuclear localisation signal (NLS) directs import into the nucleus, while a 
nuclear export signal (NES) directs export out of the nucleus. The PIC is estimated at 
roughly 56nm in diameter and so requires active, facilitated transport through the pore 
complexes (33).  The nuclear import of HIV-1 complexes will be discussed in the 
next section but, briefly, the main PIC proteins identified as potential mediators of 
nuclear import are Integrase, Viral Protein R and Matrix Protein. The accessory 
proteins Tat and Rev also require import after the initial integration step and once they 
have been translated in the cytoplasm.  
 
Once inside the nucleus, the double stranded HIV genome is targeted to be integrated 
into the host genome, and serve as the template for another round of viral replication. 
The sites within the human genome for integration to occur have been correlated with 
regions of active gene transcription, especially genes activated by HIV infection. It 
has also been revealed after global analysis that certain regions are also favoured for  
integration, with a 2.4Kb region containing 1% of integration sites (34). The 
preference for integration within active genes is not surprising, considering that the 




Integration is mediated by a large (~160S) nucleoprotein complex, with the main viral 
protein that catalyses this process being Integrase (27). As its name suggests, this 
protein is involved in integrating the viral DNA into the host genome to allow for 
productive viral replication (36, 37) . Integrase is a 32 kDa protein encoded by the pol 
gene. In the first step of integration, nucleotides are removed from the 3’ end of the 
viral DNA in a 3’end processing event. The DNA is then cleaved at the CA sequence 
of the 3’ end, resulting in a free OH that is to be bound to the chromosomal DNA. 
This processed viral DNA then attacks a phosphodiester bond present in the target 
DNA. The 3’end processing and the strand transfer reactions are both mediated by 
Integrase. Cellular repair and ligation enzymes then carry out the remaining steps to 
fully integrate the foreign DNA (38). Once this process has been completed, HIV-1 
transcription from the long terminal repeat (LTR) promoter can commence and new 
virions can be assembled and released from the infected cell.  
 
The transcription from the LTR promoter is greatly enhanced by the HIV Tat protein, 
which is a potent trans-activator and once in the nucleus it binds an RNA element 
termed the transactivation responsive element (TAR element) and enhances the 
initiation and elongation steps of HIV-1 transcription (39–41). Tat not only acts as a 
transcription factor, but also causes induction of apoptosis in CD4+ T cells, thereby 






The newly transcribed, unspliced RNA is transported out of the nucleus by the HIV 
Rev protein (44). Speculation exists as to whether RNA export is the only function of 
the Rev protein, as viral infectivity can be stimulated >1000 fold by its presence, an 
effect possibly not only due to nuclear export (45). However, mRNA transport 
appears to be the main function of the Rev protein. When bound to its mRNA, Rev 
utilises the nuclear exporter protein, Chromosome  region maintenance 1 (CRM1), to 
shuttle to the cytoplasm with its cargo (46)(47).  Here the viral mRNA is translated by 
the host translation machinery to produce viral proteins to be packaged into new virus 
particles.  
 
The late stages of the HIV-1 life cycle include intracellular transport, assembly, 
maturation and budding. The HIV Gag polyprotein is crucial to these late stage events 
and is capable of singlehandedly assembling non-infectious virus like particles (48). 
The assembly of new virions occurs at the plasma membrane  at specific membrane 
microdomains such as lipid rafts and tetraspanen-enriched microdomains (TEMs)(49). 
These are cholesterol enriched regions of the plasma membrane known to be entry 
and exit sites for pathogens (50). The Gag protein consists of four domains; the 
Matrix protein (MA), capsid (CA), nucleocapsid (NC) and p6. The MA protein is 
known to target assembly to the plasma membrane as well as being implicated in 
nuclear import of the PIC. Myristoylation of Matrix’s N terminal glycine appears to 
be the key event targeting Gag to the plasma membrane. The p6 protein is responsible 
for viral budding as the viral lipid membrane separates from the host cell membrane. 
Once assembly and budding have been completed, the newly formed virus particles 
are free to infect neighbouring susceptible targets. The auxiliary proteins Nef, Vif, 
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Vpr, Vpx and Vpu aid in increasing overall infectivity and viral replication through a 
variety of functions throughout the life cycle (51).  
 
All the steps of the HIV-1 life cycle have been extensively studied and drug targets 
identified at most of the stages. Less well understood stages at this point are the 
nuclear import of the viral PIC, as well as the nuclear import of the regulatory 
proteins.  
 
1.1.3 HIV-1 Nuclear Import 
 
HIV-1 consists of only 9.2 kb of unspliced genome, which encodes 15 proteins in 
total. This limited size has led the virus to evolve mechanisms of exploiting host 
factors and pathways in order to achieve successful replication. For example, the HIV 
LTR promoter makes use of common host transcription factors for optimal 
transcription of its inserted genome. These transcription factors include NF-κB, Sp1, 
AP-1 and many more (52). In fact, an interaction between host factors and HIV-1 are 
widespread and the ‘HIV-1-Human Protein Interaction Database’ has been 
constructed from the literature (53, 54).  
 
During the early preintegration stage of infection, the PIC requires nuclear import 
across the nuclear envelope to complete integration and subsequent replication within 
the nucleus. In the following postintegration stage, regulatory proteins such as Tat and 
Rev require nuclear import to perform their functions in the nucleus. The virus makes 
use of multiple host proteins during these steps.  
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Figure 1.7. A schematic of the NPC and the proposed import of the HIV-1 PIC containing the proteins Matrix, 
Integrase and Vpr. These three viral proteins have been identified in the literature as possible mediators of nuclear 
import but much controversy still exists. Adapted from (154).  
 
 
The main viral candidates identified in the literature as being involved in the nuclear 
import of the PIC are the HIV proteins Matrix Antigen (MA), Integrase (IN) and Viral 
Protein R (Vpr), as well as the central ‘DNA flap’/ central polypurine tract (cPPT) 
(21) (Figure 1.7). Their precise roles and the mechanisms in this process are, 
however, controversial and contradictory.  
 
 
All facilitated transport into the nucleus is regulated by the macromolecular nuclear 
pore complexes, as well as transporter proteins. In order to be recognised for import 
by a transporter, a nuclear localisation signal (NLS) is required to be present within 
the cargo. This NLS interacts with a transporter protein that then navigates 
interactions through the lumen of the nuclear pore complex to successfully ferry the 
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cargo across the nuclear membrane. Nucleoporins are by no means passive bystanders 
in the nuclear import process. They actively interact with both the cargo and nuclear 
transporters to support nuclear import, through docking and undocking reactions (55). 
Recent research revealed that selective depletion of nucleoporins 153 and 98 from 
human Jurkat lymphocytes resulted in a marked decrease in HIV-1 infection. Nup 153 
and 98 were also shown to bind the HIV-1 core, further implicating them as important 
in PIC import and possibly even integration (56, 57). Karyopherins α and β have been 
seen to bind FXFG repeat regions within the nucleoporins in vitro and in vivo. The 
NPC is the stationary phase in this process and facilitates docking and release 
reactions along the lumen of the nuclear pore (reviewed in (58)). Nuclear import can 
be competitive, with members of the same family competing for binding to 
nucleoporins as well as cargo (59).  
 
Functional NLSs have been discovered in the HIV proteins Matrix (MA) and 
Integrase (IN) that could facilitate passage of the PIC through the nuclear pore 
complex (60). The Vpr protein, however, does not seem to contain an NLS but has 
been shown to be important for PIC nuclear transport as seen when a mutant virus 
lacking Vpr failed to enter the nucleus in vitro (61). The presence of a putative NLS, 
however, is not sufficient to confer nuclear import. For instance, Hearps et al (2008) 
showed that MA fails to enter the nucleus and they propose its “NLS” serves other 
purposes such as forming higher order structures and DNA binding (62). 
Additionally, MA may be dispensable for nuclear import, as seen by the fact that 





Once the PIC has entered the nucleus and transcription is underway, accessory 
proteins such as Tat and Rev also require entry and exit from the nucleus. Both 
proteins contain arginine-rich sequences that function as NLS’s (64). Rev has shown 
to utilise different nuclear import pathways in different cellular environments (65), 
while Tat has also been described as able to diffuse passively through the NPC due to 
its small size (14kDa) (66). Apart from these proteins, a ‘DNA flap’ created during 
reverse transcription has also been implicated as a cis-determinant of HIV nuclear 
import (67). This project will focus on the nuclear import pathways employed by the 
PIC proteins IN and Vpr, as well as the regulatory protein, Tat.  
 
HIV nuclear import poses an attractive novel therapeutic target. In order for the virus 
to integrate and replicate, various key proteins must be actively imported into the 
nucleus. However, the host proteins that perform this function are intricately 
intertwined in a web of host processes that if tampered with could lead to toxicity.  
 
1.2 The Nuclear Transporter Karyopherin β1 (Kpn β1) 
 
Multiple soluble nuclear transport receptor proteins exist in the cell that shuttle cargo 
to and from the nucleus. The main family of transporters is the Karyopherin 
superfamily of proteins (59). The first discovered family member that has been 
extensively studied is Karyopherin β1 (Kpnβ1), also known as Importin β, p97 and 
yeast Kap95 (69). This particular Importin works either in concert with an adapter 
protein, Karyopherin α or alone to import cargo bearing a basic nuclear localisation 




It was first discovered in 1994 that a cytosolic protein was responsible for selective 
protein import into the nucleus (71). A year later researchers identified that the 
process of transporting NLS containing proteins into the nucleus involved association 
and dissociation  reactions driven by a RanGTP gradient (72). To allow directionality 
of transport, there exists a concentration gradient of the small GTPase, Ran. The 
binding site on Kpnβ1 for Ran overlaps the binding site for its cargo, thereby 
releasing the cargo upon Ran binding (Figure 1.8a and Figure 1.9). Ran is present at a 
high concentration in the nucleus and this allows for cargo release upon entry into the 
nucleus.  
 
Kpnβ1 is a 97kDa protein consisting of 876 amino acids that form 19 helical repeat 
motifs (HEAT repeats) of ~40 residues in length (Figure 1.8a). These HEAT repeats 
consist of right handed superhelical structures that twist and contract upon cargo or 
subunit binding (73).  Kpnβ1 contains 23 well distributed cysteine residues (68). The 
Figure 1.8. (a) Schematic of 19 HEAT repeats of Kpnβ1 showing binding sites for RanGTP, the NPC as well as 
cargo. (b) Structure of Kpnβ1 (yellow) bound to the IBB domain of Kpnα (blue). Derived from (163).  
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protein is able to bind  RanGTP at residues 1-364 (HEAT repeats 1-8) while residues 
331-876 (HEAT repeats 7-19) are responsible for Karyopherin α binding (69).  
 
 
Kpnβ1, together with Kpnα bound to the cargo, then facilitates transport through the 
nuclear pore complexes into the nucleus (Figure 1.9) (74).  Kpnβ1 also contains 
binding sites for the NPCs that allow for sequential binding reactions to facilitate 
translocation through the nuclear pores (69).  Zinc ions are essential for the  nuclear 
envelope  binding activity of Kpnβ1 (p97) (68).  
 
The binding site present on Karyopherin α for β is termed the Importin β-binding 
(IBB) domain and the crystal structure of the two proteins intimately bound has been 
solved (73). Thus, once the trimeric cargo: Kpnα: Kpnβ1 complex enters the nucleus, 
the high concentration of RanGTP causes the cargo to dissociate from Kpnα as 
RanGTP binds Kpnβ1 at the position of the IBB domain (72, 75). Kpnβ1 and Kpnα 
are exported from the nucleus, to await another round of import.  
 
Figure 1.9. Cartoon showing the dissociation of Kpnα and Kpnβ, as well as the cargo NLS, upon 
RanGTP binding in the nucleus. Picture adapted from (164).  
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There is therefore a constant cycling of the transporter proteins and a release of their 
cargo in the nucleus. Of interest, overexpression in yeast of fragments containing the 
binding regions of Karyopherin α or β resulted in sequestration of the Importin 
proteins to these fragments, as well as inhibition of cellular growth, highlighting the 
importance of this process to cellular function (76).   
 
In order for Kpnβ1 to recognise its cargo proteins, they must contain a short sequence 
of highly basic amino acids termed a nuclear localisation signal (NLS) (77). The first 
NLS to be characterised was the lysine rich ‘classical’ NLS, PKKKRKV (78). This 
canonical NLS is similar to that of the SV40 Large T antigen and is recognised by the 
60kDa protein Karyopherin α (Kpnα), which then binds to Kpnβ1 (74, 78–80).  
Kpnβ1 brings the complex to the nuclear envelope and interactions with the 
nucleoporins of the NPC to allow for nuclear import of the heterotrimer (71,76). This 
‘classical’ pathway is the best characterised nucleocytoplasmic transport pathway to 
date. Distinct NLS sequences have since been identified, such as the bipartite NLS 
discovered in nucleoplasmin that also requires the Kpnα-Kpnβ heterodimer, as well as 
other adapters being utilised by Karyopherin β. The bipartite sequence consists of two 
clusters of basic amino acids, separated by a linker region (82).   
 
Recently, it has come to light that Kpnβ1 performs many other functions in the cell 
apart from nuclear transport (83). These various roles are prevalent in the cell cycle, 
where it appears to be a negative regulator of nuclear envelope and spindle assembly 
(84). After nuclear envelope breakdown, Kpnβ1 is transported to the spindle poles. A 
disturbance in the balance of the expression of Kpnβ1 affects cellular division and 
pole assembly(85). The organisation of the microtubules into spindles is controlled by 
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special proteins termed spindle assembly factors (SAFs). Examples of these are 
TPX2, NuMA, and the kinesin XCTK2. Kpnβ1 and Kpnα inhibit spindle formation 
by sequestering these SAFs. The small GTPase, Ran, acts in an antagonistic manner 
by displacing SAFs from Kpnα or β, thereby inducing spindle assembly (83, 86). 
Kpnβ1 has also been seen to negatively regulate nuclear membrane assembly by 
inhibiting NPC assembly as well as membrane fusion, also in concert with Ran (87). 
Additionally, nuclear pore proteins do not efficiently localise to the membrane in 
Kpnβ1 mutants, further emphasising its crucial function in correct NPC assembly 
(88).  
 
1.3 Karyopherin β1 and HIV nuclear import 
 
Karyopherins have been shown to exhibit flexibility in their import pathways and 
targets, depending on the cellular context (89, 90). The HIV-1 virion may therefore 
utilise a variety of Karyopherins to achieve integration. Many different host factors 
have been suggested to import elements of the PIC. Importin 7 was seen to be 
involved in the active nuclear import of purified Reverse Transcription complexes 
(RTCs), as the PIC was previously named, in primary macrophages (91). Pull down 
studies revealed that Importin 7 binds directly to the C terminus of HIV Integrase, 
suggesting a mechanism for Importin 7’s interaction with the PIC (92).  
 
The cellular protein Lens-epithelium derived growth factor (LEDGF) has been 
implicated in facilitating nuclear import of the PIC by interacting with Integrase (93, 
94). LEDGF/p75 binds directly to Integrase and aids in its nuclear import, as well as 
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integration activity by enhancing the DNA tethering of the enzyme (93, 94).  One 
group showed that IN formed complexes with TNPO3/Importin 3 as well as Importin 
α in cultured cells transfected with Integrase and disruption of either of these 
complexes was seen to abrogate nuclear import in vitro (95).  
 
Previously, Karyopherin β1, together with Karyopherin α2, was proven to bind and 
import a Capsid protein from HPV 11, suggesting it is a pathway commonly hijacked 
by invading viruses (96).  
 
There is conflicting evidence in the literature regarding whether Kpnβ1 imports the 
karyophilic PIC proteins Matrix, Integrase and Vpr, as well as regulatory proteins 
such as Tat and Rev. In this study we focused on the regulatory HIV protein Tat and 
the PIC proteins Integrase and Vpr to determine whether Karyopherin β1 mediates 
their nuclear import.  
 
1.3.1 Tat Nuclear Import 
 
Investigation into interactions of the HIV-1 Tat protein with the Karyopherin family 
of transporters has yielded varying results in previous studies. In particular, Tat has 
been shown to contain a non-classical NLS that conferred nuclear accumulation in the 
absence of an intact nuclear envelope, suggesting that this NLS targets binding to 
nuclear components in vitro (97). The same study found that in the absence of ATP, 
this nuclear accumulation was abrogated. This suggested that Tat was utilising an as 
yet discovered method to enter the nucleus. In contrast, Truant et al. (1999)  
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demonstrated that the arginine rich NLS in the Tat protein failed to interact with the 
conventional Karyopherin α adapter, but instead bound directly to Karyopherin β1 
and that this interaction was sufficient to direct nuclear import (64). This is not 
surprising as it has since been shown that arginine rich NLSs interact directly with 
Kpnβ1(70). Interestingly, this same NLS region has been shown to confer the RNA 
binding properties to the protein necessary for its transactivation of the HIV LTR 
promoter (98). Truant and colleagues also investigated other β-like transporters, such 
as Transportin, and found that they were not involved in Tat nuclear import (64). 
Other studies have also shown that Tat is able to interact with Kpnα and Kpnβ, albeit 
in the absence of other competitors (100). The small size of the Tat protein also 
suggests that it may passively diffuse through the nuclear pore complex. This is 
indeed the case as seen by in vivo analyses of GFP tagged Tat peptide. FRAP analysis 
of nuclear/cytoplasmic exchange in energy depleted cells showed that no active 
transport mechanism contributed to the diffusion profile, which corresponded to 
benchmark passive diffusion proteins. These results prove that Tat nuclear 
accumulation is an energy independent process (66). However, GST-pull down 
studies performed in 2013 showed that Tat interacts directly with Importin 13. 
Residues 49R50K51K were identified as essential for import by this factor (100).  
 
It is possible that Tat does all of the above depending on the cellular context. 
Redundant pathways most likely exist to ensure replication and as a result of years of 




1.3.2 Integrase Nuclear Import 
 
Similarly, there is much controversy regarding the requirement of the Karyopherin 
proteins for the nuclear import of HIV-1 Integrase protein. The Integrase NLS has 
been suggested to be located at residues 161-173 due to nuclear import being 
abrogated by the presence of a synthetic peptide of this region. This region was 
sufficient to cause nuclear import of attached bovine serum albumin (BSA). This 
sequence alone, as well as full length IN interacted with Kpnα and this interaction 
could be out competed by the IN NLS as well as the SV40 NLS (101). While 
Integrase seems to contain nuclear localisation signals, its interaction with the 
Karyopherins is still under debate.  
 
HIV-1 Integrase is transported actively into the cell nucleus via a saturable 
mechanism, suggesting a cellular factor is involved. The first studied viral 
determinant of nuclear import was the Matrix protein. However, focus also shifted 
onto the Integrase protein when it was discovered that there is a direct interaction 
between tyrosine phosphorylated MA and the central domain of IN which results in 
MA incorporation into virions (102).  However, it was observed that the karyophilic 
properties of IN alone are not responsible for nuclear targeting of the PIC (103).  
Mutagenic studies also point to the C-terminal tri-Lysine region of Integrase being 
integral in nuclear targeting of viral DNA, in addition to reverse transcription and 




1.3.3 Viral Protein R (Vpr) Nuclear Import 
 
There is also conflicting evidence for the role of active nuclear import in Vpr nuclear 
transport. An early study showed that Vpr contains an as yet characterised NLS  that 
does not interact with Karyopherin alpha and suggested it utilises a distinct nuclear 
import pathway (105). A contradictory study argued that Vpr does indeed bind to 
Karyopherin α as well as being competed from this binding by the molecular 
chaperone, heat shock protein 70 (Hsp70). The binding of either Vpr or Hsp70 to a 
novel binding site present on Kpnα resulted in nuclear import of the HIV-1 PIC. This 
binding also enhanced interaction between Kpnα and MA, a crucial requirement for 
import according to these authors (106). Although the PIC proteins appear to be 
individually karyophilic in nature, one cannot underestimate the power of their 
interactions with one another to ensure import of the PIC. While useful information 
can be obtained from studying the individual proteins, one must always bear in mind 











1.4 Project Aim 
 
Much controversy surrounds the precise proteins and mechanisms involved in the 
entry of the HIV-1 viral proteins into the nucleus of target cells. In this study, the aim 
was to investigate if the nuclear transporter protein Karyopherin β1 is involved in the 
nucleocytoplasmic translocation of key HIV-1 proteins.  
 
1.5 Project Objectives 
 
(1) To investigate the transactivation capability of Tat after Kpn β1 inhibition using 
siRNA and a small molecule inhibitor.  
 
(2) To determine if targeted inhibition of Karyopherin β1 affects nuclear import of the 













CHAPTER TWO:  
MATERIALS AND METHODS 
 
 
2.1 Cell Culture 
 
2.1.1 Cell lines  
 
In order to study the transactivation capability of the HIV Tat protein, TZM-bl  
(JC53-bl) cells, a HeLa derived cell line stably expressing a firefly luciferase 
(Photinus pyralis) construct under the control of the HIV LTR promoter, were 
cultured (107). This cell line was kindly donated by Professor Carolyn Williamson, 
Medical Virology, UCT.  HeLa cells are a human cervical cancer cell line and were 










2.1.2 Tissue cell culture methods 
 
TZM-bl and HeLa  cell lines were maintained at 60-80% confluency in Dulbecco’s 
modified Eagle’s medium (DMEM) (Gibco, Paisley, Scotland) supplemented with 
10% (v/v) fetal calf serum (FCS) (Highveld Biologicals, Modderfontein, 
Johannesburg, RSA), penicillin (100 units/ml) and  streptomycin (P/S) (100 µg/ml). 
 
Cells were incubated at 37°C in a 5% CO2 incubator and were split using a 0.05% 
Trypsin-EDTA solution, which was then neutralised with DMEM. The cells were 
then pelleted by centrifugation and resuspended in 8ml fresh DMEM. 1ml of this 
solution was then added to 10ml fresh DMEM and plated in a 100mm dish. The 
remaining solution was re-centrifuged and suspended in 2ml cell freezing media 
(Appendix B). 1ml aliquots were transferred to cryovials for freezing. Cells were 
stored at -80°C for two weeks prior to long term storage in liquid nitrogen. This slow 











2.2. Short interfering RNA (siRNA)  
 
The siRNA used to silence expression of Kpnβ1 was Karyopherin β1 siRNA (h) (sc-
35736, Santa Cruz Biotechnology, Santa Cruz, CA, USA).  This siRNA consists of 
pools of three to five target-specific 19-25 nucleotide siRNAs designed to knockdown 
gene expression. As a control, non-silencing siRNA, MISSION® siRNA universal 
negative control ( sic001, Sigma-Aldrich Inc., St Louis, USA)  not complementary to 
any known mRNA sequence was used. siRNAs were received as lyophilised powders 
that were resuspended in RNAase-free water to yield working stocks of 10 µM.  
 
2.3. Drugs and Inhibitors 
 
The small molecule inhibitor used to block Kpnβ1 function was compound 43(c43). 
c43 was the result of a functional screen for small molecules that could bind Kpnβ1 
performed by our laboratory and was purchased from Molport (Riga, Latvia).  
The phorbol ester, 12-o-tetradecanoylphorbol-13-acetate (TPA), was purchased from 










2.4 Transformation and Isolation of plasmid DNA 
 
2.4.1 HIV expression vectors 
 
As a means of studying the HIV-1 proteins Tat, Integrase, Vpr and Matrix, their 
respective expression vectors were acquired according to Table 2.1.  
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Competent JM109 bacterial cells (Promega, Madison, WI, USA) were used to amplify 
plasmid DNA. 10-50 ng plasmid DNA was added to 30 µl JM109 cells and incubated 
on ice for 10-30 minutes. Thereafter the cells were heat shocked at 42°C to encourage 
DNA uptake. Cells were allowed to recover and growth was encouraged by the 
addition of 450 µl LB media and incubation at 37°C for 1 hour with shaking. 
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Thereafter, cells were ready to be spread onto agar plates containing either 30 µg/ml 
Kanamycin or 100 µg/ml Ampicillin, depending on the selection marker present in the 
plasmid. Only those cells that selectively took up the plasmid will survive in the 
antibiotic, yielding positive colonies. Plates were incubated at 37°C overnight and the 
following day individual colonies were picked and grown up in a starter culture of 
5ml LB containing either 60 µg/ml Ampicillin or 30 µg/ml Kanamycin for 6-8 hours. 
Thereafter the starter cultures were transferred into 100ml LB containing either 100 
µg/ml Ampicillin or 60 µg/ml Kanamycin and allowed to grow to late log phase 
overnight at 37°C with shaking.  
 
2.4.3 Isolation of Plasmid DNA 
 
In order to isolate and purify plasmid DNA from transformed JM109 cells, plasmid 
preparations were performed. For small scale purification for screening purposes, 
minipreps using the PureYield™ Plasmid Miniprep system (Promega) were 
performed. For medium to large scale purification for subsequent transfections, midi 
and maxi-preps were carried out. For midipreps, the PureYield™ Plasmid Midiprep 
System (Promega) was used, while for the maxipreps, the Qiagen Plasmid Maxi Kit 
was used. DNA was purified as per the manufacturer’s instructions.  
 
2.4.4 Plasmid sequence confirmation  
 
To confirm isolation of the correct plasmids, restriction digests were performed  to 
check if the correct insert was released. Digests were performed using conditions 
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optimal for each restriction enzyme and double digests carried out in compatible 
buffers only.  
 
2.4.5 Agarose gel electrophoresis 
 
Digests were run on 1% (w/v) agarose gels to confirm the correct sizes. The 1% 
agarose was melted in 1XTBE buffer for two minutes in a microwave oven. Once 
cooled, a final concentration of 0.5µg/ml ethidium bromide was added to the gel to 
visualise the DNA bands under ultraviolet (UV) light. The gel was then allowed 20 
minutes to set before samples were loaded. The gel was then run at 100V for ~1 hour 
or until desired bands were separated adequately.  
 
2.4.6 Glycerol Stocks 
 
Transformed JM109 cells were stored long term in glycerol at -80°C. A suspension of 
50% cells, 50% glycerol was made that once frozen could be used again by simply 








2.5 Molecular Cloning of Tat cDNA from pSV2-tat72 into pEGFP-C2 
 
To allow for visualisation of HIV-1 Tat, it was necessary to construct a GFP-tagged 
recombinant plasmid. Tat cDNA was thus cloned from its original pSV2-tat72 vector 
into the pEGFP-C2 vector to generate a GFP-Tat construct that would allow tracking 
of GFP-Tat localisation via fluorescence microscopy. 
 
2.5.1 Tat Primer Design 
 
To amplify Tat cDNA, primers were designed according to the sequence for the Tat 
gene provided with the pSV2-tat72 vector map. To allow for in frame ligation into 
pEGFP-C2, restriction sites (KpnI and XhoI) corresponding to sites present in the 
multiple cloning site (MCS) of pEGFP-C2 were incorporated into the primers. These 
sites were chosen as they were not present in the pGEM-T Easy plasmid used for sub 
cloning and sequencing. The sites were also not present within the Tat cDNA 
sequence. The primers were designed with the aid of the Primer Blast program on the 
NCBI website (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
 
The resulting primer sequences, with restriction sites KpnI and XhoI underlined were:  
 
F: 5’ ATC TCG AGA ATG GAA CCG GTC GAC CCG 3’ and  




2.5.2 Polymerase Chain Reaction (PCR)  
 
PCR was performed using the above primers to amplify the tat gene from 50ng of 
template pSV2-tat72 plasmid DNA. The reaction consisted of 1X PCR buffer (1.5mM 
MgCl2), 20pmol of each primer, 0.2mM dNTP’s and 1 Unit of high fidelity Pfu DNA 
polymerase (Thermo Scientific). The following conditions were then applied for the 
PCR reaction: 95°C for 5 mins, 35 cycles of 95°C for 30 seconds, 50°C for 30 
seconds and 72°C for 30 seconds and finally an extension step at 72°C for 5 minutes. 
The resulting PCR product was then subjected to electrophoresis on a 1% agarose gel. 
The size of the bands was determined using the O’Gene Ruler DNA Ladder Mix 
Marker (Fermentas Inc., Waltham, MA, USA).  
 
2.5.3 Purification of DNA from agarose gel 
 
DNA bands were visualised under low UV light (230-50Hz, Ultratec Ltd) in a Uvitec 
Light box and excised from the agarose gel using a sterile blade. The DNA band was 
purified using the Wizard® SV gel and PCR Clean-up Kit (Promega) according to the 
manufacturer’s protocol. 
 
2.5.4 A-tailing Reaction 
 
The gel purified PCR product was then subjected to an A-tailing reaction in order to 
ligate into the T-tailed region of pGEM-T-Easy (Promega). A low fidelity 
polymerase, Taq Polymerase, was thus employed. The reactions was performed using 
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6µl of the purified PCR product and 5 Units of Taq Polymerase (Stratagene, USA) in 
a reaction containing 1 X Taq buffer, 2.5mM MgCl2 and 0.2mM dATP. This reaction 
was incubated for 30 minutes at 70°C in a PCR machine and the resulting product 
directly ligated into the pGEM-T-Easy cloning vector (Promega). For this ligation, 
3µl of PCR product, 50ng of pGEM-T-Easy, 1 X Rapid Ligation Buffer, and 3 Units 
T4 DNA Ligase (Promega) were incubated at 4°C overnight.  
 
The next day 5µl of this ligation mix was transformed into 30µl competent E.Coli 
JM109 cells. The cells were first left on ice for 30 minutes and thereafter heat shocked 
at 42°C for 2 minutes. Subsequently 0.45ml Luria broth was added and the cells 
incubated for 37°C. After this incubation the cells were spread onto agar plates 
containing 100µg/ml Ampicillin, 100µl of IPTG and 20µl of X-gal. Successful 
cloning results in the disruption of the lacZ gene, resulting in white colonies as the X-
gal cannot be cleaved in the absence of β-galactosidase, which usually results in a 
blue product. Thus, white colonies were picked and grown up overnight in 5ml of LB 
media containing 100µg/ml Ampicillin. Glycerol stocks were stored the following day 
before proceeding with isolation of the plasmid DNA via minipreps, as described 
above.  
 
2.5.5 Plasmid mapping and sequence confirmation 
  
In order to verify the correct plasmid had been purified, restriction enzyme digestions 
were performed. Enzymes present in the PCR primers that would release the insert 
were used. KpnI and BamHI, both FastDigest Enzymes (Fermentas), were added to 
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1µg of each miniprep clone as well as 1X FastDigest Green Buffer (Fermentas) and 
allowed to react for 1 hour. The digests were then loaded directly onto a 1% agarose 
gel and electrophoresed for ~1hr. All clones were seen to release the 240bp Tat insert 
from the pGEM-T-Easy vector. 
 
One correct glycerol stock was then grown up and large-scale plasmid preparations 
performed using the Qiagen Maxi Kit as per the manufacturer’s instructions. 
Thereafter, sequencing was performed to validate that the insert was indeed the tat 
gene. The sequencing reaction involved 500ng template DNA (pGEM-T-Easy with 
insert), 2µl Ready Reaction Premix, 2µl 5X sequencing buffer BigDye® Terminator 
v3.1 cycle sequencing kit ( Applied Biosystems, USA) sequencing buffer, 6.4pmol 
either T7 or SP6 Primers and dH2O up to 20µl. The PCR reaction for each sample was 
then performed as follows: 96°C for 1 minute followed by 25 cycles of 96°C for 10 
seconds, 45°C for 5 seconds, and 60°C for 4 minutes, after which the PCR products 
were sent to the UCT Human Genetics Sequencing Unit.  
 
2.5.6 Ligating the Tat insert into pEGFP-C2 
 
After sequencing confirmed the correct insert was sub cloned into pGEM-T-Easy, Tat 
cDNA was cloned into the final plasmid. Firstly the insert was released from pGEM-
T-Easy by digestion with the Fermentas FastDigest restriction enzymes KpnI and 
XhoI. The final pEGFP-C2 vector was linearised with the same restriction enzymes. 
The digests were then run on a crystal violet stained gel to prevent Ultraviolet (UV) 
damage to the sticky ends. The gel and 1X TAE buffer contained crystal violet dye at 
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a concentration of 10µg/ml and the DNA was then visualised using a light box in the 
absence of UV. The released Tat insert and the linearised pEGFP-C2 plasmid were 
both gel purified using the Wizard® SV Gel and PCR clean-up System (Promega) as 
per the manufacturer’s instructions.  
The DNA was then quantitated on a NanoDrop 2000 machine and the ligation 
performed according to the following equation,  
 
𝑛𝑔  𝑣𝑒𝑐𝑡𝑜𝑟
𝑘𝑏  𝑖𝑛𝑠𝑒𝑟𝑡 ×𝑘𝑏  𝑖𝑛𝑠𝑒𝑟𝑡×𝑚𝑜𝑙𝑎𝑟  𝑟𝑎𝑡𝑖𝑜
𝑖𝑛𝑠𝑒𝑟𝑡
𝑣𝑒𝑐𝑡𝑜𝑟 = 𝑛𝑔  𝑖𝑛𝑠𝑒𝑟𝑡 
 
The ng of vector used is normally 100ng and the molar ratio of insert to vector is 
usually within the range of 1:1 to 1:10. After many attempts at optimising this ratio, it 
was found that a ratio of 60:1 worked, despite this being outside the usual range found 
in the literature. The vector and insert DNA were combined at 100ng vector and 
250ng insert DNA. Thereafter 1X Ligase buffer, 1µl 50% PEG and 5 Units T4 DNA 
Ligase, and dH2O up to 10µl were added to the DNA and the reaction was incubated 
at room temperature overnight. The following day, the entire ligation mix was 
transformed into 40µl JM109 E.coli cells as described previously, and plated onto 
agar plates containing 30µg/ml Kanamycin. Ten colonies were picked and grown up 
in 5ml LB containing 30µg/ml Kanamycin and minipreps performed. Once a correct 
clone was identified by restriction enzyme digestion to release the insert, this clone 





2.6 Transfection  
 
2.6.1 Transient Transfection of siRNA into cells 
 
TZM-bl and HeLa cells were plated at approximately 40-60% confluency (100-
120 000 cells/ 35mm dish).  Once the cells had adhered overnight, short-interfering 
RNA (siRNA) was transfected using Transfectin (Bio-rad) Transfection Reagent. For 
a 35mm dish, media was aspirated off and replaced with 1ml of fresh complete 
DMEM. For transient transfection, 0.625µl Transfectin was added to 50µl serum and 
penicillin/streptomycin free DMEM and allowed to incubate for 5 minutes. 
Thereafter, 2 µl of 10 µM siRNA (Kpnβ1 or non-silencing control) was added to the 
mixture and the reaction incubated for 15 minutes at room temperature to allow 
complex formation. The transfection mix was then added to the cells in a drop-wise 
manner, resulting in a final concentration of 20nM siRNA. Transfection mixes were 
left on the cells overnight.  
 
2.6.2 Transient Transfection of HIV-1 expression plasmids 
 
TZM-bl and HeLa cells were plated at 60-80% confluency the day before transfection 
with plasmid DNA. The HIV-1 expression vectors pSV2-Tat72, GFP-IN, GFP-Vpr, 
GFP-Gag and pEGFP-Tat were then transfected into the cells according to the 
conditions listed in Table 2. Transfection mixes were left on the cells overnight and 




Table 2.2. Table of transfection conditions used for HIV expression plasmids.  
HIV-1 Expression 
Vector 
Transfection Reagent µg plasmid DNA/35mm 
pSV2-Tat72 
(Luciferase assays) 






Genecellin Transfection Reagent  
(BioCellChallenge, Toulon, France 
2.0 
GFP-IN Genecellin Transfection Reagent 
(BioCellChallenge, Toulon, France) 
2.0 
GFP-Vpr Genecellin Transfection Reagent  




2.7 Luciferase Assays 
 
2.7.1 NFAT assays 
 
To confirm the ability of the Karyopherin β1 small molecule inhibitor c43 to block 
nuclear import, NFAT luciferase assays were performed. Nuclear factor of activated T 
cells (NFAT) is a transcription factor that translocates into the nucleus in the presence 
of intracellular calcium(111).  Nuclear translocation of NFAT occurs by recognition 
of its NLS by the Karyopherin α/β pathway (112–114). The phorbol ester 12-O-
tetradecanoylphorbol-13-acetate (TPA) and the calcium salt Ionomycin work 
synergistically to release intracellular calcium stores and activate NFAT nuclear 
import. The addition of a drug that blocks nuclear import would see a decrease in 




To perform NFAT assays, 25 000 HeLa cells per well were plated in a 24 well plate. 
The following day, 50ng GFP-NFAT (AddGene, Cambridge, MA, USA), 50ng 
NFAT-Luciferase (AddGene) and 5ng pRLTK-Renilla (Renilla reniformis) 
(Promega) were transfected per well using the Genecellin™ (BioCellChallenge) 
Transfection Reagent. For this transfection, 50µl of DMEM media, 50ng GFP-NFAT, 
50ng NFAT-Luciferase and 5ng ptK-Renilla and 0.4µl Genecellin™ 
(BioCellChallenge) Transfection Reagent were added together in a 1.5ml 
microcentrifuge tube and incubated for 15 minutes. Thereafter the mixture was added 
drop wise to the cells.  
 
The following day the Karyopherin β1 small molecule inhibitor c43 was added to the 
cells at its IC50 concentration, as well as 15µM. Cells were incubated in the presence 
of c43 overnight. The following day, TPA and Ionomycin were added to the cells at a 
concentration of 100nM TPA and 1.3uM Ionomycin per well, in the continued 
presence of c43. After 5 hours, luciferase and Renilla luminescence were measured 
using a Glomax Luminometer (Promega).  
 
2.7.2 Tat Transactivation in TZM-bl cells 
 
In order to test Tat transactivation capability, luciferase luminescence was measured 
from TZM-bl cell lysates after transient transfection of pSV2-tat72 following siRNA 
transfection. TZM-bl cells containing the HIV LTR promoter attached to the 
luciferase reporter gene were plated in a 24 well dish at 40 000 cells/well. Renilla- ptk 
was used as a transfection control at 5ng per well. Cells were washed twice with 1 X 
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PBS before addition of 1X Passive Lysis Buffer (Promega) for 15 minutes on a 
shaker. Thereafter luminescence was read on a Glomax Luminometer (Promega) 
using the Dual-Luciferase® Reporter Assay System (Promega).  According to this 
protocol, 40µl cell lysate was combined with 40 µl of the luciferase substrate, 
Luciferase Assay Reagent II (LAR II), and subsequent firefly luminescence read. In 
order to control for variations in plating and transfection, Renilla was read from the 
same wells by addition of its substrate, Stop & Glow® (Promega), which effectively 
quenched the luciferase reading and read the luminescence produced by Renilla. 
Values for each treatment were taken in quadruplicate.  
 
2.8 Immunocytochemistry and Fluorescent Microscopy 
 
In order to track the subcellular localisation of GFP-tagged Tat, IN and Vpr, 
fluorescent microscopy experiments were performed. Cells were plated at 200 000 
cells per 35mm well on coverslips in a 6 well dish. The following day the relative 
plasmids were transfected in using conditions specific to each plasmid. The next day 
cells were treated with siRNA against Kpnβ1. Cells were allowed to incubate 
overnight to ensure knockdown and media was refreshed the next day. To allow 
visualisation of Kpnβ1 in order to confirm knockdown as well as study co-localisation 
of HIV-1 proteins and Kpnβ1, the protein was stained with the cy3 secondary 
antibody. It could then be detected in the red channel on the confocal microscope. 
 
Briefly, cells were washed twice with 1XPBS and subsequently fixed in 4% 
paraformaldehyde for 20 minutes at room temperature. Following this incubation the 
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cells were washed three times with 1ml of 1XPBS. After the washing steps, the cells 
were permeabilised with 0.5% Triton X-100 for 5 minutes. Thereafter, the cells were 
washed with 1X PBS then quenched with 50mM NH4Cl for 5 minutes. The cells were 
then blocked in 0.2% gelatin in PBS for 30 minutes. Following this blocking step, 
100µl of the primary antibody (rabbit anti-Kpnβ1) diluted in blocking solution (1:200) 
was added to each coverslip and covered with a square of parafilm to prevent 
evaporation. The cells were incubated for 45 minutes in primary antibody before 
being washed a further three times with 1X PBS for 5 minutes each. The secondary 
antibody, Cy3-conjugated goat anti-rabbit antibody (Jackson ImmunoResearch, 
USA), was then added in a similar manner diluted in blocking solution (1:300) and 
incubated for 45 minutes at room temperature. After washing once with 1XPBS, the 
cells were stained with the DNA binding dye, DAPI (100ng/ml in PBS) for 5 minutes. 
After a final wash with 1XPBS, the coverslips were rinsed in dH2O and mounted in 
15µl Mowiol (Calbiochem, MerkMillipore, USA). The mounted coverslips were 
allowed to dry for a minimum of 5 hours at room temperature before viewing under 
the microscope. Slides were examined using the X100 objective under oil immersion. 
Images were captured using an LSM 510 AxioObserver (Zeiss, Oberkochen 
Germany) and Zen 2009 software (Zeiss). The Excitation wavelength was 405nm for 
DAPI, 488nm for GFP and 570nm for Cy3. In order to compare control and Kpnβ1 
siRNA treated cells, GFP fluorescent intensity in individual cells was quantitated and 









All primary antibodies and incubation conditions used are shown in Table 2.3. 
Antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA),  
The NIH AIDS Research and Reference Reagent Programme or Bio-Rad.  
 
Table 2.3. Primary and Secondary Antibody Conditions. (Kpn β1; Karyopherin β1, 
GFP; Green fluorescent protein, TBP; Tata-binding protein, IN; Integrase, milk; Elite 
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2.9.2 Protein Extraction 
 
Protein was extracted from cells using radioimmunoprecipitation assay buffer (RIPA) 
containing a 1X complete protease inhibitor cocktail (Roche, Mannheim, Germany) 
and 0.1M sodium orthovanadate phosphatase inhibitor. The cells are thus lysed while 
preventing degradation from endogenous proteolytic and phospholytic enzymes. Cell 
lysates were sonicated for approximately 10 seconds and then centrifuged for 10 
minutes at 10 000 rpm at 4°C to remove cell debris.  
 
2.9.3 Protein quantification 
 
Protein samples were quantitated using the Thermo Scientific™ Pierce™ BCA 
Protein Assay which uses bicinchoninic acid (BCA). This assay is based on the 
principle that proteins will reduce Cu2+ to Cu1+ in an alkaline medium and the reaction 
product is purple in colour and can be read at a wavelength of 595nm. This purple 
colour is formed by the chelation of two molecules of BCA with one Cu1+ ion and its 
intensity is directly proportional to the amount of protein present. The absorbance is 
read at 595nm on a Bio-Tek EL800 (Bio-Tek Instruments, Winooski, Vermont, 
Canada) reader using Gen5 software (Bio-Tek). A bovine serum albumin (BSA) 
dilution series is read in parallel to produce a standard curve of known concentrations 
plotted against absorbance values; from this the protein concentration of unknown 




2.9.4 Sodium Dodecyl Sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
 Sodium dodecyl-sulphate (SDS) polyacrylamide gels were set to a thickness of 
1.5mm. Protein samples (20 or 30µg) were electrophoresed initially on a 4% stacking 
gel and then separated on either a 10% or 15% resolving gel. The Spectra™ 
Multicolor Broad Range Protein Ladder (Thermo Scientific) was loaded to determine 
the sizes of the separated proteins. The gels were run at ~150V for 1 hour in 1X 
running buffer (recipe in Appendix B).  
 
2.9.5 Immunoblotting  
 
Proteins were then transferred horizontally onto a Hybond™-ECL™ nitrocellulose 
membrane (Amersham Life Sciences, Amersham, UK) on ice at 100V for 70 mins in 
1X Transfer buffer ( recipe in appendix). The membrane was then blocked in 5% fat 
free milk in TBST for 1 hour at room temperature on a shaker at 70rpm. This 
blocking process was to prevent non-specific binding of the antibody to the 
membrane. After blocking, the antibody was added as in table 2.3 and the membrane 
left overnight on a shaker at 4°C.  
 
The next day the membrane was washed three times for 10 minutes each with TBST. 
Secondary HRP antibody was added as in Table 2.3 for 1 hour at room temperature 
with gentle shaking. Thereafter the membrane was washed an additional three times 
for 10 minutes each. The blot was then either detected or stored at 4°C in TBST for 





For detection of specific protein bands, LumiGlO Chemiluminescent Reagent (KPL) 
or SuperSignal West Dura/ west pico (Pierce) were applied to the membrane 
according to the manufacturer’s instructions. These reagents contain the substrate, 
luminol to 3-aminophthalate, that the horse radish peroxidase enzyme oxidises to 
produce a light emitting product. This light causes the silver halide crystals in the x-
ray film to change metallic black in colour, indicating where the protein is located as 
well as the amount.  
 
2.9.7 Densitometric quantification of Western Blot bands 
 
In order to compare protein levels, quantification of protein bands was performed by 
densitometry using Image J software (NIH, USA). Protein expression levels were 











2.10 Fractionation of Nuclear and Cytoplasmic compartments 
 
As a means of studying subcellular localisation of HIV-1 proteins via Western blot 
analysis, nuclear and cytoplasmic fractions were separated. Cells were plated in 10cm 
dishes and protein was harvested by trypsinisation. Cells were then lysed and cellular 
compartments separated using the Thermo Scientific™ NE-PER™ Nuclear and 
Cytoplasmic Extraction Reagents kit (Pierce). Nuclear and cytoplasmic protein 
samples were then stored at -80°C until subjected to Western blot analysis to monitor 
HIV protein localisation following Kpnβ1 inhibition.  
 
2.11 Statistical Analysis 
 
All statistical analyses were performed using GraphPad Prism® Software. All figures 
were also generated using this programme. A p value of <0.05 was considered 
statistically significant. The ANOVA statistical tests with the Tukey post-test were 
used to determine significance between multiple samples. The Student’s t test was 












THE EFFECT OF KPNβ1 INHIBITION ON HIV-1 





The HIV Trans-activator of transcription (Tat) is an essential protein to HIV 
replication and is active in the cell nucleus. Tat functions as a unique  transcriptional 
activator by binding a cis acting RNA enhancer element, the transactivating-
responsive region (TAR), present at the 5' end of all viral transcripts (nt +1 to +59) 
(41, 115). The TAR binding domain within Tat corresponds to its Arginine-rich 
presumed NLS. Arginine-rich sequences are found in many RNA binding proteins 
and are thought to aid in RNA hairpin recognition (98, 116). Tat also enhances 
elongation of HIV transcripts by interacting with positive transcription elongation 
factor b (p-TEFb), which is known to release the paused RNA polymerase machinery, 
allowing for the elongation of the already initiated mRNA chain. It does this by 





HIV infection is characterised by depletion of CD4+ target cells, leading to immune 
deficiency. Although not fully understood, one such mechanism proposed as the 
leading cause of this depletion is apoptosis induced by the regulatory HIV protein, Tat 
(42, 43). These are not the only functions of the Tat protein, however. It appears to be 
a pluripotent protein with as yet undiscovered effects on host cells.   
 
The aim of this chapter was to investigate whether Karyopherin β1 mediates the 
translocation of the Tat protein from the cytoplasm to the nucleus, where it performs 
its trans-activating function. Inhibition of Tat nuclear import would result in a 
dramatic decrease in HIV replication rate and this pathway therefore represents a 
novel therapeutic target. Elucidating the mechanisms of this pathway would also add 
to our current understanding of HIV biology.  
 
In order to test whether Karyopherin β1 (Kpnβ1) is important for Tat nuclear import, 
we employed a functional approach to determine whether inhibition of Kpnβ1 affects 
Tat transcriptional activation activity. For Tat to exert its transactivation effects, it has 
to be present in the cell nucleus and a block to its nuclear import pathway would 
therefore cause a decrease in HIV-1 LTR promoter activity (119). To assess Tat 
transactivation capability, we employed TZM-bl cells that have been stably 
transfected with the HIV LTR promoter attached to the firefly luciferase reporter gene 



















Figure 3.1.  Diagram depicting TZM-bl cells used for Tat transactivation luciferase 
assays. TZM-bl cells are HeLa cells stably transfected with the HIV LTR promoter 
attached to the luciferase reporter gene. They also stably express the cell surface 





3.2.1 Tat transactivation capability after inhibition of Karyopherin β1 with 
siRNA  
 
We hypothesised that if Kpnβ1 is necessary for Tat nuclear import, it is expected that 
Tat transactivation capability will be reduced when Kpnβ1 is inhibited. To determine 
the requirement of Kpnβ1 for Tat transactivation, we silenced expression of Kpnβ1 
using siRNA technology complementary to the Karyopherin β1 mRNA sequence. 
Western blot analysis was performed to confirm effective knockdown of Kpnβ1 
protein levels in Kpnβ1siRNA transfected TZM-bl cells. Control siRNA (Sigma, 
sc001) composed of a scrambled non-specific sequence was used as a control for 
transfection effects. Our results show that Kpnβ1 protein expression was effectively 
inhibited with the siRNA (Figure 3.2A).    
 
To address whether Kpnβ1 was necessary for the transactivating activity of HIV-1 
Tat, a luciferase reporter assay was performed to measure the HIV-1 LTR promoter’s 
activity in TZM-bl cells. Cells were transfected with siRNA followed by transfection 
with the HIV-1 Tat expression vector (pSV2-Tat72). Luciferase activity was 
monitored 48 hours post Tat transfection and the HIV-1 LTR luciferase activity 





The results of this experiment showed that the addition of recombinant Tat protein 
resulted in a substantial and significant increase in LTR promoter activation (Figure 
3.2B). This increase was significantly abrogated by inhibition of Kpnβ1 using siRNA 
for 48 hours (Figure 3.2B). Addition of exogenous Tat resulted in a more than 5000 
fold induction in LTR promoter activity, highlighting the potency of Tat as an HIV-1 
transcriptional activator. Control experiments without the addition of Tat accounted 
for basal activity of the HIV-LTR promoter in TZM-bl cells. It also accounted for 
those host transcription factors such as NFκB and Sp1 that activate the LTR promoter 
and are also imported by Kpnβ1.  A slight reduction in basal promoter activity in the 
absence of Tat was therefore expected after Kpnβ1 siRNA. In the presence of Tat, 
Kpnβ1 siRNA significantly inhibited activation of the HIV LTR promoter. These 
































Figure 3.2. Effect of Karyopherin β1 inhibition using siRNA on Tat activity (A) 
Western blot analysis confirming knockdown of Kpnβ1 protein levels after transfection 
with Kpnβ1 siRNA for 48 hours in TZM-bl cells. (B) Relative luciferase activity as a 
measure of the HIV LTR promoter actiivty after inhibition of Kpnβ1 with siRNA. 
Addition of Tat significantly enhances promoter activity, while Kpnβ1 siRNA treatment 
significantly inhibits this effect. Results shown are the mean ± SEM of experiments 
performed in quadruplicate and repeated at least two independent times. *p<0.05. RLU: 































Interestingly, we noted that Kpnβ1 siRNA treatment resulted in a tenfold increase in 
activity of the transfection control, Renilla luciferase (Figure 3.3A, Experiment 1), 
suggesting an increase in transfection efficiency upon Kpnβ1 knockdown. We 
hypothesised that this could be due to the inhibition of Kpnβ1 resulting in aberrant 
nuclear membrane reassembly as Karyopherin β1 is integral in nuclear membrane 
assembly processes (83, 88). This would allow easier entry of cDNA into the nucleus, 
resulting in increased transfection efficiency.  
 
Under these assumptions, we speculated that transfecting with Kpnβ1 siRNA first 
may result in inflated HIV Tat transfection efficiency and in this way impact the 
interpretations of our results. We therefore repeated the experiment and all subsequent 
experiments transfecting the Tat plasmid at least 24 hours before the siRNA to ensure 
the Tat construct and pTK-Renilla would be transfected evenly throughout. When the 
experiment was performed in this order, there was no longer a significant increase in 
Renilla luciferase after Kpnβ1 siRNA transfection (Figure 3.3A, experiment 2). When 
the experiment was performed in this manner, a significant reduction in Tat 
transactivation capability upon Kpnβ1 knockdown was still observed (Figure 3.3B). 











Figure 3.3 (A) Graph showing Renilla luciferase values from promoter assays 
performed in two different ways. Experiment 1: siRNA transfected before Tat and 
Renilla plasmids resulted in an increase in transfection and resulting expression of these 
plasmids as see by the significant increase in Renilla following Kpnβ1 siRNA 
transfection. Experiment 2:  When siRNA was transfected after Tat and Renilla, this 
increase was no longer significant. All subsequent experiments were performed in the 
order of experiment 2. (B) Luciferase assay performed by transfecting Tat plasmid 
DNA before siRNA. A significant decrease in Tat transactivation capability after Kpnβ1 
inhibition is still observed. Results shown are the mean ± SEM of experiments 
performed in quadruplicate and repeated at least two independent times,  *p<0.05. RLU: 


























































3.2.2 Tat transactivation capability after inhibition of Karyopherin β1 with the 
small molecule inhibitor, c43 
 
Our laboratory has an interest in identifying small molecule inhibitors of Kpnβ1. 
Research in our group identified a small molecule, named compound 43 (c43), with 
potential to inhibit nuclear import. The c43 compound was identified using a 
computational screening approach undertaken in our laboratory that aimed to identify 
compounds that would bind the 331-364 amino acid residue region within Kpnβ1 that 
binds RanGTP, Kpnα2, as well as cargo (Figure 3.4). Compound 43 has been studied 
extensively in our laboratory as an anti-cancer drug that blocks nuclear import and the 
functions of Kpnβ1.  
 
 
This small molecule inhibitor of Kpnβ1 was thus used to further evaluate the 
requirement of the Kpnβ1 mediated nuclear import system in Tat transactivation. To 
confirm that c43 was functional at blocking nuclear import via Kpnβ1, the nuclear 
translocation of NFAT was analysed.  NFAT is a transcription factor that is imported 
into the nucleus via Kpnβ1 in response to intracellular calcium release (112).  A small 
Figure 3.4. Schematic depiction of the overlapping binding sites on Karyopherinβ1 for Karyopherin α 
and Ran-GTP. Compound c43 binds in the region of residues 331-364. Adapted from (75).  
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molecule inhibitor of Kpnβ1 would therefore interfere with NFAT nuclear 
translocation and activation of an NFAT-responsive promoter construct. To stimulate 
NFAT translocation to the nucleus, TPA and Ionomycin were used to release 
intracellular calcium and the effect of Kpnβ1 inhibition using c43 monitored by 
measuring NFAT promoter activity. In this manner, c43 was shown to significantly 
block NFAT transcriptional activity in a dose dependent manner (Figure 3.5A).  This 
result served as validation that c43 inhibits Kpnβ1 mediated nuclear transport.  
 
To investigate the effect of c43 on Tat transactivation capability, TZM-bl cells 
transfected with a Tat construct were treated with 10µM (the IC50 of c43) and 15µM 
of c43 and the relative luciferase activity analysed as a measure of HIV LTR promoter 
activity. Our results showed that c43 caused a significant decrease in Tat 
transactivation function at both 10µM and 15µM concentrations (Figure 3.5B). These 

















































Figure 3.5 (A) NFAT assays showing inhibition of NFAT nuclear translocation after 
treatment with the Kpnβ1 inhibitor c43 at 10µM and 15µM. (B) Promoter assay showing 
a decrease in Tat transactivation capability after inhibition of Kpnβ1 with c43 treatment 
in TZM-bl cells. Results shown are the mean ± SEM of experiments performed in 
quadruplicate and repeated three independent times.*p <0.05, *** p < 0.01. RLU: 









0µM c43 + TPA/Ionomycin
10µM c43 - TPA/Ionomycin
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3.2.3 Cloning of HIV-1 Tat into the expression vector pEGFP-C2  
 
Having shown that inhibition of Kpnβ1 reduces Tat transactivating activity, we next 
wanted to further assess whether Kpnβ1 mediates Tat nuclear import using a 
complementary technique, like fluorescence microscopy. In order to visualise Tat, a 
GFP-Tat fusion protein was required. To insert the Tat gene into the GFP expression 
vector pEGFP-C2, the cDNA from the pSV2tat72 plasmid was first PCR amplified. 
As the restriction sites present in the final vector and the insert were not compatible, a 
PCR approach was selected that would allow addition of restriction sites into the 
primers that would then be compatible with the final vector.  
 
Firstly, primers were designed that flanked the start and stop codons of the Tat gene 
as well as restriction sites being introduced that corresponded to the MCS of the 
pEGFP-C2 plasmid and allowed for in frame insertion of the insert into the final 
vector. The restriction sites chosen were KpnI and XhoI as these created sticky ends 
and were not present within the coding region of either the Tat gene or the final 
vector. A PCR product of approximately 240 bp was retrieved from a 1% agarose gel 
electrophoresis of the PCR reaction (Figure 3.6A, Lane 2). This product was then 



















































Figure 3.6 (A) 1% agarose gel showing the PCR product obtained from PCR amplification of 
the HIV-1 Tat gene from the pSV2-tat72 plasmid using primers flanking the gene and 
containing restriction sites for further cloning into the final pEGFP-C2 vector. Lane 1: O’Gene 
Ruler DNA ladder mix (Fermentas) Lanes 2: PCR amplified Tat cDNA product (240bp) (B) 
Schematic depiction of pGEM-T Easy containing the Tat insert cDNA. (C) 1% agarose gel 
showing digests to screen for the Tat insert. Lane 1: Mass Ruler DNA ladder mix(Fermentas), 
Lanes  2, 4 and 6: 1µg undigested pGEM-T Easy-Tat. Lanes 3, 5 and 7: 1µg PGEM-T Easy-Tat 




























Following purification and quantification, the PCR product was subjected to an A-
tailing reaction that would allow ligation into the pGEM-T Easy shuttle vector (Figure 
3.6B). This then allowed for selection of colonies that contained the insert via 
blue/white screening, as well as sequencing to confirm the insert was correct. Clones 
were also screened by restriction digestion with KpnI and XhoI to release the insert 
(Figure 3.6C). A correct pGEM-T Easy-Tat clone was grown up for large-scale 
plasmid DNA preparation using the Qiagen Maxi Plasmid Extraction Protocol. The 
purified plasmid DNA was then sequenced to confirm the correct insert had been 
ligated and that no errors were introduced in the PCR reaction.  
 
Plasmid DNA from the sequenced clone was then digested with KpnI and XhoI 
enzymes to release the Tat cDNA for subsequent cloning into the pEGFP-C2 
expression vector (Figure 3.7A, Lanes 4 and 5). The pEGFP-C2 final vector was 
similarly digested to allow linearisation (Figure 3.7A, Lane 10) and ligation of 
compatible sticky ends of the Tat insert into the MCS of the final vector. These 
digests were then run on a 1% agarose gel stained with crystal violet dye to prevent 
degradation of sticky ends by ultraviolet light exposure. Figure 3.7A is representative 
of the digestion as we were unable to capture the crystal violet gel optimally for 
visualisation. The appropriate bands were then excised from the gel and purified and 





















































Figure 3.7 (A) 1% agarose gel containing digestions of pGEM-T Easy-Tat and pEGFP-C2 with 
KpnI and XhoI. Lane 1: O’Gene Ruler DNA Ladder Mix (Fermentas), Lane 2: Undigested 
pGEM-T Easy-Tat, Lane 3: Empty, Lanes 4-5: pGEMT-T Easy-Tat digested with KpnI and XhoI 
to release the 240bp Tat cDNA insert. Lane 6: Empty, Lane 7: O’Gene Ruler DNA Ladder Mix 
(Fermentas). Lane 8: Undigested pEGFP-C2. Lane 9: Empty, Lane 10: pEGFP-C2 digested with 
KpnI and XhoI. (B) Schematic depiction of the recombinant pEGFP-C2-Tat plasmid, pEGFP-Tat. 
The Tat insert was inserted into the MCS of pEGFP-C2 by restriction digestion with the enzymes 
KpnI and XhoI. The GFP-Tat fusion protein is under the control of the CMV promoter. (C) 1% 
agarose gel electrophoresis picture of pEGFP-Tat digested with KpnI and XhoI restriction 
enzymes to release the Tat insert. Lane 1: O’Gene Ruler DNA ladder mix (Fermentas). Lane 2: 
Undigested pEGFP-Tat (4940bp). Lane 3: pEGFP-Tat digested with KpnI and XhoI, releasing the 
240bp insert.  
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The ligation mix was then transformed into E.Coli JM109 cells and plated onto agar 
plates containing the pEGFP-C2 selection antibiotic, Kanamycin. The resulting 
colonies were subsequently screened by digestion with KpnI and XhoI to release the 
240 bp Tat insert (Figure 3.7C, Lane 3). The recombinant pEGFP-Tat plasmid would 
therefore express the HIV-1 Tat protein fused at the N-terminus to the fluorescent 
protein GFP under the control of the CMV promoter and allows for monitoring of Tat 
by confocal microscopy.  
 
3.2.4 Analysis of the subcellular localisation of GFP-Tat after Kpnβ1 inhibition 
in HeLa cells.  
 
The cloned pEGFP-Tat recombinant plasmid was transfected into HeLa cells to 
monitor subcellular localisation of GFP-Tat. HeLa cells were chosen as they are 
known for their high transfection efficiency and they are the parent cell line to TZM-
bl cells. They also exhibit an elongated morphology that makes them superior for 
studying cytoplasmic localisation over TZM-bl cells that are much smaller and more 
rounded in morphology.  
 
pEGFP-Tat was transfected into HeLa cells before treatment with either control or 
Kpnβ1 siRNA. The small molecule, c43, could not be used in this instance as it is a 
fluorescent compound making fluorescent data analysis in the presence of c43 




Immunocytochemical staining for Kpnβ1 expression was done using a cy3-conjugated 
secondary antibody. Our results show that the Importin is concentrated on the nuclear 
membrane (Figure 3.8, red channel). This is in line with its function in importing 
cargo through the nuclear pores. Knockdown was observed upon Kpnβ1 siRNA 
treatment as shown by a decrease in intensity of the cy3 fluorophore (Figure 3.8, red 
channel). This knockdown was quantitated for at least 20 individual cells that were 
also successfully transfected with the GFP-Tat plasmid, using Image J software.  
 
Fluorescent images were captured forty eight hours after siRNA transfection, to 
ensure adequate Kpnβ1 knockdown (the Kpnβ1 half-life is approximately 24 hours). 
Variation in intensity of fluorescence from cell to cell was observed due to the nature 
of transient transfections. To account for this, the ratio of nuclear/cytoplasmic 
fluorescent intensity was determined for individual cells using the Zen Software 
(Zeiss) and the mean nuclear/cytoplasmic ratio for GFP-Vpr and GFP-IN determined 
for twenty cells in each experimental condition. These values were then compared 
between control and Kpnβ1 siRNA treated groups. To visualise the nuclear 
localisation in each cell the nucleic acid stain, DAPI, was used. In order to study the 
localisation of the GFP-tagged HIV proteins in relation to the nucleus, the GFP and 
DAPI signals were merged to determine the extent of the GFP nuclear localisation.  
 
It was observed that in control siRNA transfected cells, the recombinant GFP-tagged 
Tat protein localised predominantly in the nucleus. Interestingly the protein 
concentrated in the nucleoli of the cell nucleus (Figure 3.8, green channel). This is not 
a surprising observation due to Tat being an RNA-binding protein (98). Inhibition of 
Kpnβ1 resulted in a marginal increase in GFP-Tat cytoplasmic localisation (Figure 
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3.8, green channel).  Quantification of Kpnβ1 fluorescence in control and Kpnβ1 
siRNA transfected cells showed a significant decrease in its expression upon Kpnβ1 
knockdown (Figure 3.9A). Quantification of GFP-Tat fluorescence and analysis of the 
ratio of nuclear/cytoplasmic GFP-Tat fluorescence revealed a decrease in Tat 
nuclear/cytoplasmic fluorescence when Kpnβ1 was inhibited, suggesting that it 
favours localisation to the cytoplasm upon Kpnβ1 knockdown. This decrease, 
























Figure 3.8. Confocal Microscopy images of HeLa cells transfected with the pEGFP-Tat plasmid and 
subsequently treated with either control or Karyopherin β1 siRNA. Cells were viewed 48 hours after 
siRNA treatment at 100X magnification under oil. Images were taken using a Zeiss LSM 510 






























Figure 3.9. (A) Confirmation of Karyopherin β1 knockdown via siRNA 
technology. Quantitation of Cy3 fluorescent intensity was performed using Zen 
Software (Zeiss) for control and Kpnβ1 siRNA treated cells. (n=20) (B) 
Quantification of the  ratio of nuclear/cytoplasmic intensity for control and Kpnβ1 
knockdown cells (n=20). Results shown are the mean ± SEM (n=20 cells) of 





























3.3 Discussion  
 
The work presented in this study was aimed at determining whether Karyopherin β1 
mediates the nuclear import of the HIV-1 Tat protein. The small size of Tat (14kDa) 
suggests that passive diffusion through the nuclear pore complexes could account for 
its nuclear import. Indeed, recent studies in HeLa cells showed that Tat can  enter the 
nucleus via passive diffusion (120).  Tat, however, bears an arginine rich nuclear 
localisation signal (NLS) that directs the import of heterologous proteins when fused 
to the NLS (98). This NLS has also been shown to bind Kpnβ1 directly in a single 
study (64), as well as perform the TAR RNA binding function during transactivation 
of the HIV LTR promoter (98). Recently, evidence for the nucleocytoplasmic 
shuttling of Tat by Importin 13 has also been shown via co-localisation and pull down 
assays (100). Due to the controversy surrounding nuclear import of the HIV proteins, 
additional studies need to be undertaken to conclusively elucidate the import 
mechanisms of Tat. A growing body of evidence is suggesting that HIV utilises more 
than one pathway to enter the cell nucleus, implying redundant pathways may have 
evolved to allow for nuclear entry in a more controlled and timely manner (90, 121).  
 
This study found that when the nuclear transporter, Karyopherin β1, was inhibited 
using siRNA technology, as well as a small molecule inhibitor, c43, Tat nuclear 
function was significantly abrogated.  Our findings also showed a trend towards a 
decrease in the ratio of nuclear/cytoplasmic fluorescent intensity of GFP-Tat, 




In analysing Tat transactivation using luciferase assays, we found that Kpnβ1 
inhibition appeared to affect (significantly increase) the subsequent transfection 
efficiency of the cells. The fact that the transfection efficiency of Renilla luciferase as 
well as Tat was affected by Kpnβ1 siRNA could be due to the role of Karyopherin β1 
in nuclear membrane assembly, as well as the cell cycle. It has been shown that 
mitosis is intricately linked to efficiency of cationic lipid-mediated transfection of 
DNA, as when the nuclear membrane is broken down, DNA can more readily enter 
the nucleus (122). The role of Kpnβ1 in the cell cycle is well documented. Work in 
our laboratory showed that inhibition of Kpnβ1 expression results in a prolonged 
mitotic arrest (123). It is thus plausible that Kpnβ1 inhibition causes cells to arrest in 
mitosis, allowing for increased entry of transfected DNA. Due to this effect we 
performed all subsequent experiments transfecting the Tat plasmid DNA before 
Kpnβ1 siRNA.  
 
To validate the ability of the c43 molecule to inhibit nuclear import via Kpnβ1, we 
utilised an NFAT assay. NFAT is a transcription factor that is imported by Kpnβ1 and 
the inhibition of its transcriptional activity was an indicator that its nuclear import was 
being inhibited. However, it is important to note that this same effect would be seen if 
c43 was a general inhibitor of transcription. To account for this, Renilla luciferase 
was used as an internal control during subsequent luciferase assays. The transcription 
of Renilla is controlled by the thymidine kinase minimal promoter and therefore if 
c43 was a general inhibitor of transcription, it would have caused a decrease in 
Renilla luciferase levels. We found this not to be the case and could safely conclude 
that c43 selectively blocked nuclear import and not transcription. Although a further 
control that could have been included would have been a luciferase reporter construct 
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not requiring nuclear import of a factor/s for its activation. Inhibition of Kpnβ1 with 
c43 would then not have affected transcription of this promoter and proved that this is 
indeed a Kpnβ1 specific effect.  
 
Previous studies of GFP-tagged Tat showed that the GFP tag had no effect on the 
protein’s nuclear localisation or function as a transactivator of transcription (124). Our 
results showed that Tat localised to the nuclei, specifically the nucleoli of HeLa cells. 
The nucleolar localisation of Tat is probably due to the RNA binding capability of this 
protein, which also happens to be the Arginine-rich NLS region of the protein (98).  
Our observation of the nuclear and nucleolar localisation of Tat is in line with that 
observed in other studies (120, 124, 125).  
 
To account for basal promoter activity due to host transcription factors that activate 
the HIV LTR promoter such as Sp1 and NFκB, we performed our promoter assays in 
the absence of Tat as well. It was seen that the decrease in promoter activity after 
Kpnβ1knockdown in the absence of Tat was marginal in comparison to the decrease 
in the presence of Tat. This slight decrease is probably due to the fact that these host 
transcription factors are also imported by Kpnβ1 and the decrease in promoter activity 
could also in part be due to a decrease in their nuclear import. We could therefore 
account the significant decrease in the LTR promoter activity following Kpnβ1 
inhibition in the presence of Tat, to a decrease in Tat transactivation function and not 
host factors alone.  
 
Taken together, these promoter results show that Kpnβ1 is necessary for optimal Tat 
nuclear function and could possibly be involved in Tat’s nuclear import in TZM-bl 
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cells. Tat function, however, was not completely abolished following Kpnβ1 siRNA. 
These results suggest that while Kpnβ1 may be one pathway the Tat protein employs 
to enter the nucleus, it is likely not the only one. An alternative explanation is that 
knockdown of Kpnβ1 protein expression using siRNA is not always absolute and 
residual Kpnβ1 protein is still expressed and could continue to import Tat into the 
nucleus to perform its functions.  
 
Similarly, we observed a trend towards a change in GFP-Tat subcellular localisation 
following Kpnβ1 siRNA knockdown in HeLa cells. The fact that this was not 
significant could also be due to the unsilenced Kpnβ1 proteins continuing to import 
GFP-Tat into the nucleus. Alternatively, Tat could not rely as heavily on Kpnβ1 in 
HeLa cells than in TZM-bl cells. TZM-bl cells are HeLa cells that have been stably 
transfected with key HIV specific proteins, as well as the LTR promoter attached to a 
luciferase construct. Although they should thus behave similarly, it is noted that these 
stable transfections led to a significant change in the morphology of these cells, 
suggesting further reaching biochemical changes as well that could account for this 
discrepancy. The fact that these results show a trend towards decreased nuclear import 
of Tat in HeLa cells following Kpnβ1 siRNA suggests that Kpnβ1 may be one of 
many importers in this cell line able to import HIV Tat into the nucleus.  
 
Our results support current literature reporting that Tat is imported by Karyopherin 
β1. A key study showed that Tat binds directly to Kpnβ1, without the need for the 
Kpnα adapter molecule (64). Our findings do not, however, distinguish between direct 
binding to Kpnβ1 or binding via the adapter protein, Karyopherin α (Kpnα). Further 
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investigation would be needed, possibly inhibiting Kpnα selectively, to draw 
conclusions regarding which sub-pathway the Tat protein utilises.  
 
These results are in contrast to a study suggesting Tat nuclear import is ATP-
dependent but independent of the Karyopherin pathway (97). However, this study 
utilised HTC rat hepatoma cells and analysed a Tat-NLS-β-galactosidase fusion 
protein. It could be that Tat uses a range of import pathways depending on the cell 
type and context and this could explain why our results are in contrast to this finding. 
A recent study also showed that Tat can bind Kpnα/Kpnβ in the absence of 
competitors, whereas this property is silenced in the cellular environment (126). 
Unless these specific competitors are less active in the TZM-bl cell line we used, our 
findings are in contradiction to this hypothesis.  
 
In conclusion, we present evidence that Tat transactivation function is significantly 
decreased when Kpnβ1 is knocked down. This could be due to a decrease in the 
nuclear import of Tat. There is controversy in the literature regarding the exact 
mechanisms involved in Tat import and this could be due to many redundant 
pathways operating simultaneously, as well as variations depending on the cell type 
and context. The nuclear import of HIV Tat is therefore a complex and diverse 
process and thoughts on designing a therapy to block this step should possibly target a 







CHAPTER FOUR:  
THE EFFECT OF KPNβ1 INHIBITION ON 
LOCALISATION OF HIV-1 PIC PROTEINS 





In order for productive viral infection to occur, the HIV Pre-integration complex 
(PIC), composed of double stranded viral DNA and proteins, requires entry into the 
host cell nucleus. Too large for passive diffusion, PICs must utilise the cellular 
nuclear transport machinery, as well as the Nucleoporins (NUPs), to cross the nuclear 
membrane via the nuclear pore complexes (NPC) (127). The details of this process 
are, however, still unclear. The main viral proteins identified as possibly importing 
the HIV PIC into the nucleus are Viral Protein R, Integrase and Matrix (21). 
However, evidence in the literature is contradictory on this matter,  with studies both 
supporting and refuting the role of each of these components in the nuclear 
translocation of the PIC (128, 129). There is also disagreement on whether the nuclear 
transporter, Karyopherin β1, is involved in the import of the PIC via these proteins 




We aimed to investigate this process in our laboratory and focused on the PIC 
proteins, Viral Protein R (Vpr) and Integrase (IN) and their individual nuclear 
transport when Karyopherin β1 is inhibited. Although the Matrix protein has also 
been proposed to be involved in importing the PIC, it requires the viral Protease (PR) 
enzyme for its post-translational processing. HIV-1 Protease cleaves the Gag 
polyprotein precursor (Pr55Gag) into the mature p17 Matrix (MA), p24 Capsid (CA), 
p7 Nucleocapsid (NC) and p6 proteins (48, 134, 135). These constructs were not 
available to us hence Matrix nuclear transport was not included in this investigation.  
 
To determine the role of Karyopherin β1 in Vpr and IN nuclear import, we 
investigated the subcellular localisation of the GFP-tagged proteins of interest 
following Kpnβ1 siRNA mediated knockdown.  If Kpnβ1 is necessary for their 
nuclear import, we anticipated a decrease in the nuclear localisation of these proteins, 














4.2.1 Optimisation of transfection conditions for pEGFP-Vpr and pEGFP-IN  
 
GFP expression plasmids containing the HIV-1 Vpr and IN cDNA were obtained 
from the NIH Aids Reagent Programme and Dr Zeger Debyser (University of Leuven, 
Belgium), respectively.  
 
To study the localisation of GFP-Vpr and GFP-IN, the plasmids were transfected into 
HeLa cells and GFP fluorescence examined by fluorescence microscopy. Initially, the 
GFP signal was poor for both plasmids, suggesting non-optimal transfection 
conditions. This was unlike the GFP-Tat plasmid we used which did not require 
optimisation. Transfection conditions were thus optimised using varying cell lines, 
transfection reagents, amount of plasmid DNA transfected, as well as the confluency 
of the cells upon transfection. Transient transfections were therefore performed with 
either pEGFP-Vpr or pEGFP-IN plasmids at 0.5µg, 1µg and 2µg concentrations using 
the Genecellin Transfection Reagent (BioCellChallenge) (Figure 4.1 and 4.2). 2µg 
plasmid DNA was determined to yield optimal transfection of both plasmids and was 
used in subsequent experiments. The localisation of GFP-Vpr fluorescence was found 
to be cytoplasmic with some nuclear fluorescence (Figure 4.1), while GFP-Integrase 
fluorescence localised predominantly to the cell nuclei (Figure 4.2). This greatly 
improved the transfection efficiency, although we only ever observed approximately 




To improve the percentage of GFP positive cells, we attempted to construct a stable 
cell line stably expressing the GFP-Integrase fusion protein. Selection for cells 
containing the plasmid was performed with G418 (Geneticin) and cell sorting via 
FACS analysis sorted GFP positive cells (Addendum III, page 100). Unfortunately 
very few GFP fluorescent cells were obtained, despite the cells being grown for weeks 
in G418 antibiotic. It was suspected that the cells had retained the antibiotic resistance 
gene, whilst removing the unnecessary GFP-IN cDNA.  
 
We therefore performed all subsequent experiments using the optimised conditions 
for transient plasmid transfections. We found the experimental conditions that worked 
best for this study involved the use of Genecellin as a transfection reagent, 2µg of 











































1µg  GFP-Vpr 
2µg  GFP-Vpr 
DAPI GFP (Vpr) MERGE 
Figure 4.1. Optimisation of transfection conditions for HIV protein expression plasmid 
pEGFP-Vpr transfected into HeLa cells and visualised via fluorescence microscopy. A 
titration was performed using 0.5, 1 and 2 µg plasmid DNA transfected into 35mm plates 
containing 120 000 cells using the transfection reagent, Genecellin (BioCellChallenge). 
2µg was determined to yield the best transfection. GFP-Vpr localised predominantly to 













Figure 4.2. Optimisation of transfection conditions for HIV protein expression plasmid 
pEGFP-IN transfected into HeLa cells and visualised via fluorescence microscopy. A 
titration of 0.5µg,1µg and 2µg of plasmid DNA/35mm plate was transfected into 
120 000 HeLa cells using the transfection reagent Genecellin (BioCellChallenge). 2µg 
was determined to yield the best transfection. Top two panels were taken at 40X 
magnification, bottom panel was taken at 100X magnification. GFP-IN localised 
predominantly to the nuclei. DAPI:nuclear stain; GFP: GFP-IN.  
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To determine the effect of Kpnβ1 inhibition on Vpr and Integrase subcellular 
localisation, confocal microscopy was performed following Kpnβ1 inhibition with 
siRNA. The Kpnβ1 inhibitor, c43, could not be used as it fluoresces in the green 
channel due to its quinoxaline side chain and would therefore interfere with the signal.  
 
Plasmids were transfected into HeLa cells using the optimised transfection conditions, 
followed by transfection of control or Kpnβ1 siRNA the following day. We noted that 
after transfection the number of cells present was significantly lower in the transfected 
dishes than in the untransfected dishes. However, sufficient transfected cells were 
obtained such that we could analyse the results. As can be observed in Figure 4.3, the 
number of cells present after transfection is significantly lower than the untransfected 
images, with the cells appearing more flattened and elongated. It was clear that many 














4.2.2 Subcellular localisation of GFP-Vpr following Kpnβ1 inhibition  
 
The GFP-Vpr protein localised diffusely between the cytoplasmic and nuclear 
compartments in control siRNA transfected HeLa cells (Figure 4.3, control siRNA 
green channel). Although GFP-Vpr appears predominantly cytoplasmic upon 
visualisation, quantification of the mean fluorescent intensity of the whole cell based 
on its phase contrast outline revealed that the mean intensity was roughly equal for the 
nuclear and cytoplasmic compartments.  
 
To visualise Kpnβ1, immunocytochemistry staining was performed using a Cy3-
conjugated secondary antibody and the intensity levels evaluated between control and 
knockdown cells (Figure 4.3, red channel). As in chapter 3, we observed Kpnβ1 
localisation concentrated to the nuclear membrane. A decrease in fluorescent intensity 
in the Red Cy3 channel was observed in the Kpnβ1 siRNA-transfected cells, 
confirming Kpnβ1 knockdown. This decrease in intensity was quantified using the 

































Figure 4.3. Confocal microscopy images of HeLa cells transfected with GFP-Vpr plasmid and 
either untreated (top panel), control siRNA treated(middle panel) or Kpnβ1 siRNA treated 
(bottom panel). Images were taken on a Zeiss LSM 510 AxioObserver confocal microscope at 
100X magnification under oil, 48 hours following siRNA transfection. GFP-Vpr was seen to 




Quantification of the ratio of nuclear/cytoplasmic GFP-Vpr fluorescent intensity 
showed that Kpnβ1 knockdown had no effect on GFP-Vpr localisation (Figure 4.4B). 
While our results showed no change in GFP-Vpr localisation, we had concerns 
regarding the pEGFP-Vpr plasmid construct as the subcellular localisation we 
observed is in contradiction to the literature. Several studies have shown that Vpr 


























Figure 4.4. (A) Confirmation of Kpnβ1 siRNA knockdown. Cy3 fluorescent intensity 
was quantitated using Zen Software (Zeiss) for control and Kpnβ1 siRNA treated cells. 
(B) Quantitation of nuclear/cytoplasmic fluorescent intensity in cells transfected with 
GFP-Vpr (as shown in Figure 4.2) using Zen Software (Zeiss). N=20. No change was 
observed after Kpnβ1 siRNA treatment. Results show are the mean ± SEM (n=20 cells) 























































4.2.3 Subcellular localisation of GFP- Integrase following Kpnβ1 inhibition 
 
As was observed in previous experiments, the number of cells after transfection with 
GFP-IN plasmid and siRNA was significantly lower than the untreated images 
(Figure 4.5, phase contrast and DAPI channels).  
 
In control siRNA transfected cells, GFP-Integrase (GFP-IN) was seen to localise 
predominantly to the nuclei of cells, with some cytoplasmic localisation observed . Of 
particular interest, the pattern of GFP-IN localisation appeared punctate, with small 
spheres of GFP-Integrase aggregating within the cells (Figure 4.5, green channel).  
 
Kpnβ1 siRNA knockdown was confirmed by quantitation of the Cy3 fluorescent 
intensity. A comparison between control siRNA and Kpnβ1 siRNA treated cells 
showed a significant reduction in Kpnβ1 fluorescent signal (Figure 4.6A). Upon 
Kpnβ1 siRNA knockdown, we observed an increase in cytoplasmic accumulation of 
GFP-IN but not complete exclusion from the nucleus (Figure 4.5). When the nuclear/ 
cytoplasmic intensity ratios were quantitated and analysed, a significant decrease in 
the nuclear/cytoplasmic fluorescent intensity ratio in the Kpnβ1 siRNA treated cells 
was observed (Figure 4.6B).  This suggested that Kpnβ1is required, in part, for the 

















Figure 4.5. Confocal microscopy images of GFP-Integrase transfected into HeLa cells. Top panel: 
Untreated, middle panel :Control siRNA treated, bottom panel: Kpnβ1 siRNA treated. ). Images 
were taken on a Zeiss LSM 510 AxioObserver confocal microscope at 100X under oil, 48 hours 
following siRNA transfection. Experiments were performed at least two independent times. DAPI: 
denotes the nucleus; Cy3: Kpnβ1; GFP: GFP-IN. 
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Figure 4.6. (A) Confirmation of Kpnβ1 siRNA knockdown. Cy3 fluorescent intensity 
was quantitated using Zen Software (Zeiss) for control and Kpnβ1 siRNA treated 
cells. (B) Quantitation of the ratio of nuclear/ cytoplasmic mean fluorescent intensity 
in cells transfected with GFP-IN. Kpnβ1 siRNA caused a significant decrease in 
nuclear/cytoplasmic ratio of fluorescent intensity of GFP-IN. Results show are the 

























































The significant change observed by confocal microscopy in GFP-IN localisation upon 
Kpnβ1 knockdown, was confirmed using an independent experiment. Western blot 
analysis, using protein extracts after nuclear and cytoplasmic separation, was 
therefore performed to validate the microscopy result. HeLa cells were transfected 
with the pEGFP-IN plasmid, followed by transfection with control or Kpnβ1 siRNA 
for 48 hours. Nuclear and cytoplasmic protein fractions were then isolated from the 
cells and subjected to Western blot analysis. A ‘whole cell’’ protein sample was also 
harvested from a dish treated in parallel. Kpnβ1 knockdown was confirmed by 
Western blot analysis using the Kpnβ1 antibody (Figure 4.7A, top panel). HIV-1 
Integrase was detected using a GFP specific antibody as we were unable to detect IN 
using the IN antibody obtained from the NIH repository (Figure 4.7A, second panel 
from top). Although GFP-IN localised predominantly in the nucleus of transfected 
cells in our fluorescent studies, it also localised to the cytoplasm. Thus we observed 
GFP-IN in the nuclear and cytoplasmic protein fractions, albeit slightly more in the 
nuclear fraction (Figure 4.7A).  
 
Analysis of GFP-IN in the nuclear protein compartment revealed a decrease in the 
nuclear localisation after Kpnβ1 inhibition compared to control siRNA transfected 
cells.  Interestingly, the nuclear loading control, TBP, also decreased (Figure 4.7A). 
This decrease in TBP following Kpnβ1 knockdown has been seen previously in our 
lab and appears not to be due to uneven loading and could be due to a decrease in 
TBP nuclear import. TBP has been shown to be imported into the nucleus by the 
Karyopherins, Kap114p (mammalian Importin 9), Kap123p (Karyopherin β2) and 





Figure 4.7. (A) Representative Western blot analysis  of whole cell, cytoplasmic and 
nuclear protein fractions. Karyopherin β1 protein knockdown was seen in all cellular 
compartments.  GFP-Integrase decreases in the nuclear fraction after Kpnβ1 inhibition 
with siRNA. Tata-binding protein (TBP) also decreases. Coomassie staining of the gel 
shows even loading. (B) Quantitation of the GFP-IN bands in the nuclear protein 
fractions from four independent Western blots shows a significant reduction in the 
nuclear GFP-IN protein levels of Kpnβ1siRNA treated cells compared to control 
siRNA treated cells. Results show are the mean ± SEM for experiments performed 

























It has been seen to utilise alternative pathways when one of these is absent and could 
quite possibly also utilise Kpnβ1, although this has not been shown. The other known 
nuclear loading controls are also imported by Kpnβ1, namely Histones H1 and H3 
(141, 142) and PCNA (143). To ensure that the results obtained were not due to 
loading differences, a coomassie stain of the gel was included to show similar protein 
levels across the lanes. 
 
We did not observe an increase in the cytoplasmic GFP-IN following Kpnβ1 
knockdown possible due to the fractionation method excluding the nuclear membrane 
or the accumulated GFP-IN could be targeted for degradation.  Β-tubulin was used as 
the whole cell and cytoplasmic loading control (Figure 4.7A).  
 
Quantification of the nuclear GFP-IN levels was performed on four separate 
experiments and compared between the control and Kpnβ1 siRNA treated lanes. 
Levels could not be normalised to the loading control, TBP and so loading was seen 
to be roughly even between control and Kpnβ1 via coomassie staining. The power of 
this result is derived from the decrease in nuclear GFP-IN following Kpnβ1 
knockdown being observed four independent times. This decrease was found to be 
statistically significant (Figure 4.7B).  
 
These results show via two independent experiments that the nuclear localisation of 
GFP-Integrase decreases following knockdown of Kpnβ1. Taken together, these 





4.3 Discussion  
 
The results presented in this chapter were aimed at elucidating whether the nuclear 
transporter protein, Kpnβ1, mediates the nuclear import of the PIC proteins Viral 
Protein R (Vpr) and Integrase (IN).  The precise mechanisms of Vpr and Integrase 
nuclear transport are yet to be determined as there is much controversy surrounding 
this topic in the literature.  
 
To determine whether Kpnβ1 mediates the import of Vpr or IN, we performed 
knockdown studies, inhibiting Kpnβ1 using siRNA technology. HeLa cells were 
transfected with the HIV expression vectors pEGFP-Vpr and pEGFP-IN and the 
localisation of GFP-Vpr and GFP-IN observed, respectively. We then studied viral 
protein localisation following inhibition of Kpnβ1 with siRNA via confocal 
microscopy. Kpnβ1 knockdown was also confirmed by quantitation of the Cy3 
fluorescent intensity between the control and Kpnβ1 siRNA treated cells. We also 
performed Western blot analysis on nuclear and cytoplasmic protein fractions 
following Kpnβ1 siRNA transfection to analyse GFP-IN subcellular localisation.  
 
GFP-Vpr was seen to localise diffusely throughout the cell with a slight cytoplasmic 
accumulation. This is in contrast to the literature where most studies observe HIV-1 
Vpr to localise to the cell nuclei as well as the perinuclear region (144). Interestingly, 
our observation is more in accordance with the Simian Immunodeficiency Virus  
(SIV) Vpr which has been seen to localise uniformly between the cytoplasm and the 
nucleus of transfected cells (30). Although the C-terminus of Vpr contains several 









to function as an NLS; instead it seems that the nuclear import function of Vpr is 
determined by the N-terminal region that is required for protein–protein interactions 
(147, 148). The N terminus of Vpr has been recognised as being crucial to the nuclear 
targeting and import abilities of this protein (145). As our construct contained GFP 
fused to the N terminus of Vpr, this could have possibly reduced the nuclear targeting 
functions of the protein. This contradiction with the literature was also initially 
thought to be due to our use of HeLa cells to perform our transient transfections. 
However, previous work using a GFP-tagged Vpr construct transiently transfected 
into HeLa cells saw GFP-Vpr localising to the nucleus of transfected cells (30). It is 
also possible that the integrity of the plasmid has been compromised, leading to an 
alteration in subcellular localisation that is more similar to that of GFP itself, known 
to be diffusely localised throughout the cell. We did have trouble with transfection 
efficiency with this construct and it is also possible that the poor transfection led to 
overexposure of background fluorescence not entirely due to GFP-Vpr.  
 
In this study we found that inhibition of Kpnβ1 had no effect on the nuclear 
localisation of GFP tagged Vpr, however this conclusion requires further validation, 
possibly with an alternative construct whose fusion protein’s localisation matches 
other reports.  
 
Vpr has been suggested to utilise the classical Kpnα/β pathway as it associated with 
Kpnα in a solution binding assay (61). Indeed, Vpr has consistently been shown to 
interact with Kpnα (106, 132, 149). Alternatively, Vpr contains novel NLSs and is 
able to utilise two import pathways distinct from the classical Kpnα mediated 
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pathway (150). The precise mechanisms of Vpr nuclear import via the host machinery 
are therefore still being investigated.  
 
The role of Vpr in directing the nuclear import of the PIC is still uncertain. However, 
multiple reports attest to its vital role in this process (61). Some studies have, 
however, shown that Vpr is not needed for nuclear import of the PIC in HeLa cells 
specifically (30). This could be the case in this study as we performed our 
experiments in HeLa cells and found Vpr not to concentrate to the nuclei or be 
imported via Kpnβ1.  It has also been suggested that Vpr acts together with Matrix to 
determine import of the PIC. It was observed that when either Vpr or Matrix were 
independently mutated, viral infectivity was not affected. When both were mutated, 
nuclear localisation of viral nucleic acids was greatly attenuated, suggesting a 
redundancy in PIC nucleophilic determinants (149).  
 
The GFP tagged Integrase protein localised predominantly to the nucleus in HeLa 
cells transiently transfected with the pEGFP-IN plasmid. This localisation is in 
accordance with previous studies supporting its karyophilic nature (30, 94, 109). We 
also noted aggregates of GFP fluorescence that made the signal appear punctate. This 
could possibly be due to Integrase spontaneously forming multimers as it does during 
the Integration reaction. Indeed, Integrase has been shown to form stable tetramers in 
human cells to accomplish integration of vDNA into the host chromosome (151, 152) 
 
While Integrase seems to contain nuclear localisation signals (153), they were proven 
not to be transferable and it is speculated that its karyophilic properties stem from its 
interaction with cellular factors, such as LEDGF/p75 (154). The nature of Integrase’s 
92 
 
NLSs is also under debate. It has been proposed to contain a non-canonical NLS that 
is not recognised by the classical import pathway (153), as well as an NLS that 
interacts directly with Kpnα (60, 155). 
In this study we observed GFP-IN localisation to be significantly affected by 
knockdown of Kpnβ1 using siRNA technology. The ratio of GFP-IN 
nuclear/cytoplasmic fluorescent intensity was calculated for individual cells due to the 
differences in fluorescent intensity between cells. This ratio significantly decreased 
following Kpnβ1 knockdown, suggesting a role for Kpnβ1 in Integrase nuclear 
import. Possible reasons for the fact that GFP-IN was not entirely excluded from the 
nucleus could be that the inhibition of Kpnβ1 was not always 100% and the residual 
protein left is still available to import GFP-IN into the nucleus. Alternatively, some 
cells may have taken up the plasmid DNA but not the siRNA.  
 
The result for GFP-IN was further validated by Western Blot analysis. A significant 
reduction in nuclear protein levels of GFP-IN was observed following knockdown of 
Kpnβ1. These findings support studies showing that GFP-IN is imported by Kpnβ1 
(60), while contrasting evidence that shows that IN nuclear localisation does not 
involve the Karyopherin superfamily (156). Depienne et al (2001) observed IN to 
interact directly with Importin α and that import of the PIC can be blocked by an 
NLS-IN peptide (155). However, Bukrinsky et al (1992) suggest that HIV Integrase is 
not  essential to the process of PIC nuclear import (31). The controversy surround this 
issue is possibly due to the flexible use of multiple alternative pathways that exist for 
nuclear import of PIC proteins. Integrase has also been shown to be imported by 




In conclusion, this study suggests that Vpr does not require Kpnβ1 for its nuclear 
import in HeLa cells. Through two independent methods we show that Integrase 
localisation is affected by an inhibition of the nuclear transporter, Kpnβ1. This 
suggests Kpnβ1 is involved in the import of recombinant Integrase protein. We are 
cognisant that this may not be the case in vivo in HIV target cells and that the effects 
of the PIC entity as a whole may alter this process.  
 
These results further suggest that the nuclear import of HIV proteins is a complex and 
multifaceted process that requires future investigation and novel techniques of study 
(90). It also appears that, like many viral proteins, Vpr and IN utilise multiple 


















CHAPTER FIVE:  





Nuclear import is a crucial step in the viral life cycle. Unique but redundant NLS 
signals reside within the viral PIC proteins Vpr, MA and IN that could potentially 
direct nuclear import through the nuclear pores. To date, understanding of this process 
has been impeded by a failure to establish links between viral and host proteins 
involved in this process. This study aimed to determine whether Karyopherin β1 is 
involved in the nuclear import of the HIV regulatory protein Tat and the pre-
integration complex proteins Viral Protein R and Integrase.  
 
Initially, HIV was thought to require nuclear membrane dissolution in order to enter 
the host cell nucleus, much like the other oncogenic retroviridae family members. 
Since the discovery that HIV can infect non-dividing cells, the active nuclear import 
of the viral components through an intact nuclear membrane has been a subject of 
intense research. The karyophilic nature of these proteins has allowed researchers to 
exploit their nuclear targeting properties. For example, HIV Tat has become a widely 
used molecular carrier, allowing nuclear targeting of a variety of cargoes (158, 159). 
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Despite this intense research, an agreement on a precise model of PIC, as well as HIV 
regulatory protein, nuclear import remains elusive. This may be due, in part, to the 
redundant nature of this process. It appears that HIV uses the multiple nuclear import 
pathways present in the host cell in a flexible manner (89, 90).  
.  
The flexible nature of this import process is observed in the multitude of transporter 
proteins able to bind and import HIV proteins. The HIV Tat protein has been shown 
to bind Karyopherins α/β (64, 99), Importin 13 (100), as well as enter the cell via 
passive diffusion (99, 120). Studies suggest Integrase nuclear import is mediated by 
numerous host proteins, including Kpnα/β (131) (60, 101), Importin 7(92), 
LEDGF/p75 (94) and Transportin 3 (95). Similarly, Vpr has been suggested to enter 
the nucleus via Kpnα/β (61, 132), as well as direct binding to the nucleoporins (150). 
Further redundancy exists in that the karyophilic determinants of PIC nuclear import 
all function to ensure PIC so that if one fails to direct nuclear import, the others will 
compensate. For example, mutation of either Matrix or Vpr is inconsequential to 
nuclear import, as replication is still consistent with wild-type levels. When both were 
mutated, however, viral replication was severely attenuated (149). This redundancy 
and flexibility allow the virus to replicate in a range of cell contexts.  
 
Our findings suggest that Kpnβ1 is necessary for Tat transactivation capability and 
possibly its import. The importance of Kpnβ1 for HIV LTR activation is a novel 
finding. However, its inhibition did not result in complete abrogation of promoter 
activation via Tat. This suggests that Tat is still able to enter the nucleus via other 
pathways. Alternatively, this could be due to siRNA knockdown of protein expression 
rarely being 100%. Low levels of Kpnβ1 not silenced by the siRNA could still have 
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been present that could continue to import Tat into the nucleus to activate the LTR 
promoter. Similarly, although inhibition of Kpnβ1 resulted in a significant decrease in 
the nuclear/cytoplasmic ratio of GFP-IN, this protein was not excluded from the 
nucleus altogether. Again this suggests that IN was still able to enter the nucleus by 
other means or that the residual Kpnβ1 continued to import these proteins, albeit at a 
reduced efficiency.  
 
A prophylactic vaccine against HIV has proven problematic due to the high mutation 
rate of the virus. This has led to a high rate of emergence of strains resistant to current 
drugs. There is therefore a need for novel targets and therapies until a cure can be 
obtained. Nuclear import represents an attractive novel target (160). However, due to 
the importance of the nuclear import pathways to cell functioning, toxicity could be a 
concern when inhibiting these host pathways. Agents should possibly be designed to 
target the interface between viral proteins and host Importins.  
 
In summary, our findings support other studies showing Kpnβ1 to be necessary for 









5.2 Future Perspectives 
 
Future work stemming from this study includes studying the interactions between 
Kpnβ1 and the HIV proteins Tat and Integrase to determine the mode of binding and 
whether the classical Kpnα/Kpnβ pathway is utilised for their import or it they bind 
directly to Kpnβ1. Pseudovirus studies using GFP tagged virions could also answer 
the question of whether Kpnβ1 inhibition affects replication rates of the virus. To 
further determine Kpnβ1’s role in overall viral infectivity, overexpression of Kpnβ1 
and the effects of this on HIV protein nuclear import, as well as viral replication rate 
could be studied. These experiments could determine whether targeting a host nuclear 
importin such as Kpnβ1 could have a negative impact on HIV replication. Inhibiting 
the host nuclear import machinery could, however, have an adverse effect on the 
normal functioning of host cells. An ideal target would involve selecting one that has 
limited effects on normal host cells. Experiments in our laboratory investigating 
Kpnβ1 as an anticancer target have shown that selective inhibition of this protein via 
siRNA and a targeted drug approach is toxic to cancer cells but to a significantly 
lesser extent to normal cells (161), Van der Watt, unpublished), suggesting that 
Kpnβ1 could be such a target.  
 
Targeting host nuclear import pathways necessary for the HIV life cycle in 







Appendix I:  Solutions 
 
Bacterial Solutions 
Luria Broth Medium (1L) 
10 g Tryptone 
5 g Yeast Extract 
1mM NaOH 
Up to 1l with dH2O 
Autoclave 
 
Luria Broth Agar (1L) 
 
10 g Tryptone 
5 g Yeast Extract 
1mM NaOH 
15g Agar 
Up to 1l with dH2O 
Autoclave 




0.072 g IPTG 
3ml dH2O 
Filter sterilised (0.2µM filters) 










1 mg Ampicillin 
10ml dH2O 
Filter-sterilise 




















10mM Tris-Cl, pH 8.0 





55g Boric Acid 
7.4g EDTA 
Up to 1l with dH2O 
 
1 % agarose gel 
1g Agarose 
100ml 1 X TBE 
Microwave until melted and clear 
Allow to cool for 10 minutes 
5µl Ethidium Bromide 
Pour into gel cast 
 
 
Tissue Culture Solutions 
Cell freezing media (50ml) 
5ml FCS 






5.75g Na2HPO4. 7H2O 
1g KH2PO4 




Protein Harvesting Solutions 
RIPA Buffer 
150mM Sodium Chloride 
1% Triton X-100 
1% Sodium Deoxycholate 
0.1% SDS 
10mM Tris-Cl, pH 7.4 
 
Harvesting RIPA buffer 
1mM Na2VO3 
1 X Protease Inhibitor Coctail (PI) (Roche) 
 
Western Blot Solutions 
4% Stacking Gel 
7.3ml dH20 
1.25ml 1M Tris-Cl pH 6.8 
100µl 10% SDS 
1.3ml 30% Acrylamide 
120 µl 10% Ammonium Persulphate 
12µl Temed 
 
10% Separating Gel 
5.5ml dH20  
7.5ml 1M Tris-Cl, pH 8.8 
200µl 10% SDS 
6.7ml 30% Acrylamide 
400µl 10% APS 
40µl Temed 
 
1M Tris pH 6.8 
60.5g Tris 
300ml dH2O 
pH with concentrated HCl to pH 6.8 








1M Tris pH 8.8 
60.5 g Tris 
300ml dH2O 
pH with concentrated HCl to pH 8.8 
Up to 500ml with dH2O 
 
 
4 X Loading Dye 
250 mM Tris-Cl, pH 6.8 
6% SDS 





10X Running Buffer 
20g Glycine  
31.6g Tris 
5ml 10% SDS 
Up to 500ml with dH20 
 
10X Transfer Buffer 
72g Glycine 
19g Tris 
Up to 500ml with dH2O 
 
1X Transfer Buffer 




Coomassie Staining Solution 
0.024% Coomassie Brilliant Blue 
90% dH2O 








1 X TBST 
30ml 5M NaCl 
50ml 1M Tris, pH 7.5 
500µl Tween-20 
920 ml dH2O 
 
1 M Glycine, pH 2.5 
37.54 g Glycine 
500ml dH2O 
pH with concentrated HCl to pH 2.5  
 
Immunofluorescence Solutions 






0.5% Triton X-100 
500µl Triton X-100 

















Appendix II: Protein and DNA markers 
 
 
Figure IIA.  SDS-PAGE band profile of the Thermo Scientific Spectra 
Multicolour Broad Range Protein Ladder. Images are from a 4-20% Tris-glycine 
gel (SDS-PAGE) and subsequent transfer to membrane. This ladder was used to 
determine the molecular weight of proteins separated by an SDS-PAGE gel for 




Figure IIB: DNA Ladder (O’Generuler DNA ladder mix, ready to use 
(Fermentas). This ladder was used in molecular cloning to determine sizes of 










File: Data.001 Log Data Uni ts: Linear Values
Sample ID: NEG CONTROL Patient ID: 
Acquisition Date: 25-Mar-13 Gate: G1
Gated Events: 7790 Total Events: 10000






File: Data.002 Log Data Uni ts: Linear Values
Sample ID: GFP-IN HELA PRE SORT Patient ID: 
Acquisition Date: 25-Mar-13 Gate: G1
Gated Events: 5645 Total Events: 10000






Figure III: Data from FACS cell sorting of GFP-IN transfected HeLa cells.(A) Scatter plot 
showing gating of cell parameters. (B) Negative control histogramof GFP negative HeLa 
cells. (C) GFP-IN transfected HeLa cells pre sorting. M1 represents the GFP negative 
population and M2 represents the GFP positive cell population. We were unable to produce a 









1.  Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, 
Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, 
Montagnier L. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk 
for acquired immune deficiency syndrome (AIDS) Sci. 220 :868–871. 
2.  Popovic M, Sarngadharan MG, Read E, Gallo RC. 1984. Detection, isolation, and 
continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS 
and pre-AIDS. Science 224:497–500. 
3.  WHO, UNAIDS, Unicef. 2011. Global HIV/AIDS Response: Epidemic update and 
health sector progress towards universal Access. 
4.  UNAIDS World AIDS Day Report. 2012. UNAIDS 2012 Global Report. 
5.  Jr PF, KM D, Moorman, AC, Al. E. 1998. Declining Morbidity and Mortality among 
Patients with Advanced Human Immunodeficiency Virus Infection. N. Engl. J. Med. 
405–412. 
6.  Kent SJ, Reece JC, Petravic J, Martyushev A, Kramski M, De Rose R, Cooper D 
a, Kelleher AD, Emery S, Cameron PU, Lewin SR, Davenport MP. 2013. The 
search for an HIV cure: tackling latent infection. Lancet Infect. Dis. 13:1–8. 
7.  Le Douce V, Janossy A, Hallay H, Ali S, Riclet R, Rohr O, Schwartz C. 2012. 
Achieving a cure for HIV infection: do we have reasons to be optimistic? J. 
Antimicrob. Chemother. 67:1063–74. 
106 
 
8.  Chun T-W, Davey RT, Ostrowski M, Justement S, Engel D, Mullins JI, Fauci AS. 
2000. Relationship between pre-existing viral reservoirs and the re-emergence of 
plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 
6:757–761. 
9.  De Clercq E. 2009. The history of antiretrovirals  : key discoveries over the past 25 
years. Rev. Med. Virol. 19:287–299. 
10.  Ji J, Loeb LA. 1992. Fidelity of HIV-1 Reverse Transcriptase Copying RNA in Vitro. 
Biochemistry 31:954–958. 
11.  Bebenek K, Wilson SH, Kunkelg TA. 1993. Error-prone Polymerization by HIV- 1 
Reverse Transcriptase. J. Biol. Chem. 268:10324–10334. 
12.  Frankel AD, Young JAT. 1998. HIV-1  : Fifteen Proteins and an RNA. Annu. Rev. 
Biochem. 67:1–25. 
13.  Arhel N, Kirchhoff F. 2010. Host proteins involved in HIV infection  : New 
therapeutic targets. Biochim. Biophys. Acta 1802:313–321. 
14.  Hutter G, Nowak D, Mossner M, Ganepola S, Müßig A, Allers K, Schneider T, 
Hofmann J, Kücherer C, Blau O, Blau IW, Hofmann WK, Thiel E. 2009. Long-
Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation. N. Engl. 
J. Med. 360:692–698. 
15.  Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, Gallien S, Lin 
NH, Giguel FF, Lavoie L, Ho VT, Armand P, Soiffer RJ, Sagar M, Lacasce AS, 
Kuritzkes DR. 2013. Long-term reduction in peripheral blood HIV type 1 reservoirs 
107 
 
following reduced-intensity conditioning allogeneic stem cell transplantation. J. Infect. 
Dis. 207:1694–702. 
16.  Buonaguro L, Tornesello ML, Buonaguro FM. 2007. Human immunodeficiency 
virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and 
therapeutic implications. J. Virol. 81:10209–19. 
17.  Wertheim JO, Worobey M. 2009. Dating the age of the SIV lineages that gave rise to 
HIV-1 and HIV-2. PLoS Comput. Biol. 5:e1000377. 
18.  Lewis PF, Emerman M. 1994. Passage through Mitosis is Required for 
Oncoretroviruses but Not for the Human Immunodeficiency Virus. J. Virol. 68:510–
516. 
19.  Weinberg JB, Matthews TJ, Cullen BR, Malim MH. 1991. Productive Human 
Immunodeficiency Virus Type 1 (HIV-1) Infection of Nonproliferating Human 
Monocytes. J. Exp. Med. 174:1477–82. 
20.  Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, Lieberman 
J, Elledge SJ. 2008. Identification of Host Proteins Required for HIV Infection 
Through a Functional Genomic Screen. Science (80-. ). 319:921–926. 
21.  Sherman MP, Greene WC. 2002. Slipping through the door: HIV entry into the 
nucleus. Microbes Infect. 4:67–73. 
22.  Doms RW, Moore JP. 2000. HIV-1 Membrane Fusion: Targets of Opportunity. J. 
Cell Biol. 151:F9–14. 
108 
 
23.  Gomez C, Hope TJ. 2005. The ins and outs of HIV replication. Cell. Microbiol. 
7:621–626. 
24.  Maddon PJ, Dalgleish AG, Mcdougai S, Clapham PR, Axelll R. 1986. The T4 
Gene Encodes the AIDS Virus Receptor and Is Expressed in the Immune System and 
the Brain. Cell 47:333–348. 
25.  Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson 
WA, Sodroski J. 1998. A Conserved HIV gp120 Glycoprotein Structure Involved in 
Chemokine Receptor Binding. Science (80-. ). 280:1949–1953. 
26.  Arhel N. 2010. Revisiting HIV-1 uncoating. Retrovirology 7:1–10. 
27.  Bowerman B, Brown PO, Bishop JM, Varmus HE. 1989. A nucleoprotein complex 
mediates the integration of retroviral DNA. Genes Dev. 3:469–478. 
28.  McDonald D, Vodicka M a, Lucero G, Svitkina TM, Borisy GG, Emerman M, 
Hope TJ. 2002. Visualization of the intracellular behavior of HIV in living cells. J. 
Cell Biol. 159:441–52. 
29.  Fernandez J, Gärtner K, Becker A, Danckaert A, Munier S, Zambo A, Shorte S, 
Jacob Y, Charneau P, Arhel NJ. 2013. HIV-1 capsid interacts with cytoskeletal-
associated proteins for intracytoplasmic routing to the nucleus. Retrovirology 10:P34. 
30.  Depienne C, Roques P, Créminon C, Fritsch L, Casseron R, Dormont D, 
Dargemont C, Benichou S. 2000. Cellular Distribution and Karyophilic Properties of 
Matrix, Integrase, and Vpr Proteins from the Human and Simian Immunodeficiency 
Viruses. Exp. Cell Res. 260:387–95. 
109 
 
31.  Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya a G, 
Haggerty S, Stevenson M. 1992. Active nuclear import of human immunodeficiency 
virus type 1 preintegration complexes. Proc. Natl. Acad. Sci. U. S. A. 89:6580–4. 
32.  Feldherr CM, Kallenbach E, Schultz N. 1984. Movement of a Karyophilic Protein 
through the Nuclear Pores of Oocytes. J. Cell Biol. 99:2216–2222. 
33.  Miller MD, Farnet CM, Bushman FD. 1997. Human immunodeficiency virus type 1 
preintegration complexes  : studies of organization and composition. J. Virol. 71:5382–
5390. 
34.  Schröder ARW, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. 2002. HIV-1 
Integration in the Human Genome Favors Active Genes and Local Hotspots. Cell 
110:521–9. 
35.  Felsenfeld G, Boyes J, Chung JAY, Clarkt D, Studitsky V. 1996. Chromatin 
structure and gene expression. Proc. Natl. Acad. Sci. U. S. A. 93:9384–9388. 
36.  Ellison V, Brown PO. 1994. A stable complex between integrase and viral DNA ends 
mediates human immunodeficiency virus integration in vitro. Proc. Natl. Acad. Sci. U. 
S. A. 91:7316–20. 
37.  Craigie R. 2001. HIV Integrase , a Brief Overview from Chemistry to Therapeutics. J. 
Biol. Chem. 276:23213–23216. 
38.  Krishnan L, Engelman A. 2012. Retroviral Integrase Proteins and HIV-1 DNA 
Integration. J. Biol. Chem. 287:40858–40866. 
110 
 
39.  Harrich D, Garcia J, Mitsuyasu R, Gaynor R. 1990. TAR independent activation of 
the human immunodeficiency virus in phorbol ester stimulated T lymphocytes. EMBO 
J. 9:4417–23. 
40.  Berkhout B, Gatignol A, Rabson AB, Jeang K-T. 1990. TAR-independent 
activation of the HIV-1 LTR: Evidence that Tat requires specific regions of the 
promoter. Cell 62:757–767. 
41.  Brady J, Kashanchi F. 2005. Tat gets the “green” light on transcription initiation. 
Retrovirology 2:69. 
42.  Sramkoski RM, Abhay H, Lederman MM, Scott F, James W. 1995. HIV Type 1 
Tat Protein Induces Apoptosis and Death in Jurkat Cells. AIDS Res. Hum. 
Retroviruses 11:443–450. 
43.  Bartz SR, Emerman M. 1999. Human Immunodeficiency Virus Type 1 Tat Induces 
Apoptosis and Increases Sensitivity to Apoptotic Signals by Up-Regulating 
FLICE/Caspase-8. J. Virol. 73:1956–63. 
44.  Malim MH, Hauber J, Le S-Y, Maizel J V, Cullen BR. 1989. The HIV-1 rev trans-
activator acts through a structured target sequence to activate nuclear export of 
unspliced viral mRNA. Lett. to Nat. 338:254–257. 
45.  Blissenbach M, Grewe B, Hoffmann B, Brandt S, Uberla K. 2010. Nuclear RNA 
Export and Packaging Functions of HIV-1 Rev Revisited. J. Virol. 84:6598–604. 
111 
 
46.  Askjaer P, Jensen TH, Nilsson J, Englmeier L, Kjems J. 1998. The Specificity of 
the CRM1-Rev Nuclear Export Signal Interaction Is Mediated by RanGTP. J. Biol. 
Chem. 273:33414–22. 
47.  Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M, Nishida 
E. 1997. CRM1 is responsible for intracellular transport mediated by the nuclear 
export signal. Lett. to Nat. 390:308–11. 
48.  Freed EO. 1998. HIV-1 Gag Proteins  : Diverse Functions in the Virus Life Cycle. 
Virology 15:1–15. 
49.  Mañes S, del Real G, Lacalle R a, Lucas P, Gómez-Moutón C, Sánchez-Palomino 
S, Delgado R, Alcamí J, Mira E, Martínez-A C. 2000. Membrane raft microdomains 
mediate lateral assemblies required for HIV-1 infection. EMBO Rep. 1:190–6. 
50.  Rosenberger CM, Brumell JH, Finlay BB. 2000. Microbial pathogenesis: lipid rafts 
as pathogen portals. Curr. Biol. 10:R823–5. 
51.  Seelamgari A, Maddukuri A, Berro R, de la Fuente C, Kehn K, Deng L, Dadgar 
S, Bottazzi EM, Ghedin E, Pumfery A, Kashanchi F. 2004. Role of Viral 
Regulatory and Accessory Proteins in HIV-1 Replication. Front. Biosci. 9:2388–2413. 
52.  Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ. 2000. A compilation 
of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic 
Acids Res. 28:663–668. 
53.  Ptak RG, Fu W, Sanders-Beer BE, Dickerson JE, Pinney JW, Robertson DL, 
Rozanov MN, Katz KS, Maglott DR, Pruitt KD, Dieffenbach CW. 2008. 
112 
 
Cataloguing the HIV Type 1 Human Protein Interaction Network. AIDS Res. Hum. 
Retroviruses 24:1497–502. 
54.  Fu W, Sanders-Beer BE, Katz KS, Maglott DR, Pruitt KD, Ptak RG. 2009. 
Human immunodeficiency virus type 1, human protein interaction database at NCBI. 
Nucleic Acids Res. 37:D417–D422. 
55.  Radu A, Moore MS, Blobel G. 1995. The Peptide Repeat Domain of Nucleoporin 
Nup98 Functions as a Docking Site in Transport across the Nuclear Pore Complex. 
Cell 81:215–22. 
56.  Chook YM, Blobel G. 2001. Karyopherins and nuclear import. Curr. Opin. Struct. 
Biol. 11:703–15. 
57.  Maeso R, Ashwanth F, Cereseto A. 2013. Role of nucleoporins in nuclear import and 
3D location of HIV-1 in the nuclear compartment. Retrovirology 10:P53. 
58.  Corbett AH, Silver PA. 1997. Nucleocytoplasmic transport of macromolecules. 
Microbiol. Mol. Biol. Rev. 61:193–211. 
59.  Moroianu J. 1998. Distinct Nuclear Import and Export Pathways Mediated by 
Members of the Karyopherin β Family. J. Cell. Biochem. 70:231–239. 
60.  Gallay P, Hope TJ, Chin D, Trono D. 1997. HIV-1 infection of nondividing cells 
through the recognition of integrase by the importin / karyopherin pathway. Proc. Natl. 
Acad. Sci. U. S. A. 94:9825–9830. 
113 
 
61.  Popov S, Rexach M, Zybarth G, Reiling N, Lee M a, Ratner L, Lane CM, Moore 
MS, Blobel G, Bukrinsky M. 1998. Viral protein R regulates nuclear import of the 
HIV-1 pre-integration complex. EMBO J. 17:909–17. 
62.  Hearps AC, Wagstaff KM, Piller SC, Jans DA. 2008. The N-Terminal Basic 
Domain of the HIV-1 Matrix Protein Does Not Contain a Conventional Nuclear 
Localization Sequence But Is Required for DNA Binding and Protein Self-
Association. Biochemistry 47:2199–2210. 
63.  Reil H, Bukovsky a a, Gelderblom HR, Göttlinger HG. 1998. Efficient HIV-1 
replication can occur in the absence of the viral matrix protein. EMBO J. 17:2699–708. 
64.  Truant R, Cullen BR. 1999. The Arginine-Rich Domains Present in Human 
Immunodeficiency Virus Type 1 Tat and Rev Function as Direct Importin β-
Dependent Nuclear Localization Signals. Mol. Cell. Biol. 19:1210–1217. 
65.  Gu L, Tsuji T, Jarboui MA, Yeo GP, Sheehy N, Hall WW, Gautier VW. 2011. 
Intermolecular masking of the HIV-1 Rev NLS by the cellular protein HIC  : Novel 
insights into the regulation of Rev nuclear import. Retrovirology 8:1–13. 
66.  Cardarelli F, Serresi M, Bizzarri R, Giacca M, Beltram F. 2007. In Vivo Study of 
HIV-1 Tat Arginine-rich Motif Unveils Its Transport Properties. Mol. Ther. 15:1313–
1322. 
67.  Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. 2000. 




68.  Chi NC, Adam EJ, Adam SA. 1995. Sequence and Characterization of Cytoplasmic 
Nuclear Protein Import Factor p97. J. Cell Biol. 130:265–74. 
69.  Kutay U, Izaurralde E, Bischoff FR, Mattaj IW, Görlich D. 1997. Dominant-
negative mutants of importin-β block multiple pathways of import and export through 
the nuclear pore complex. EMBO J. 16:1153–63. 
70.  Palmeri D, Malim MH. 1999. Importin β Can Mediate the Nuclear Import of an 
Arginine-Rich Nuclear Localization Signal in the Absence of Importin α. Mol. Cell. 
Biol. 19:1218–1225. 
71.  Görlich D, Prehn S, Laskey RA, Hartmann E. 1994. Isolation of a protein that is 
essential for the first step of nuclear protein import. Cell 79:767–778. 
72.  Rexach M, Blobel G. 1995. Protein Import into Nuclei: Association and Dissociation 
Reactions Involving Transport Substrate, Transport Factors, and Nucleoporins. Cell 
83:683–92. 
73.  Cingolani G, Petosa C, Weis K, Müller CW. 1999. Structure of importin-β bound to 
the IBB domain of importin-α. Nature 399:221–9. 
74.  Moroianu J, Blobel G, Radu A. 1995. Previously identified protein of uncertain 
function is karyopherin α and together with karyopherin β docks import substrate at 
nuclear pore complexes. Proc. Natl. Acad. Sci. U. S. A. 92:2008–2011. 
75.  Moroianu J, Blobel G, Radu A. 1996. Nuclear protein import: Ran-GTP dissociates 
the karyopherin αβ heterodimer by displacing α from an overlapping binding site on β. 
Proc. Natl. Acad. Sci. U. S. A. 93:7059–7062. 
115 
 
76.  Enenkel C, Schülke N, Blobel G. 1996. Expression in yeast of binding regions of 
karyopherins α and β inhibits nuclear import and cell growth. Proc. Natl. Acad. Sci. U. 
S. A. 93:12986–91. 
77.  Adam SA, Geracet L. 1991. Cytosolic proteins that specifically bind nuclear location 
signals are receptors for nuclear import. Cell 66:837–847. 
78.  Kalderon D, Roberts BL, Richardson WD, Smith a E. 1984. A Short Amino Acid 
Sequence Able to Specify Nuclear Location. Cell 39:499–509. 
79.  Dingwall C, Sharnick S V, Laskey RA. 1982. A polypeptide domain that specifies 
migration of nucleoplasmin into the nucleus. Cell 30:449–458. 
80.  Kalderon D, Richardson WD, Markham AF, Smith AE. 1984. Sequence 
requirements for nuclear location of simian virus 40 large-T antigen. Nature 311:33–
38. 
81.  Imamoto N, Tachibana T, Matsubae M, Yoneda Y. 1995. A Karyophilic Protein 
Forms a Stable Complex with Cytoplasmic Components Prior to Nuclear Pore 
Binding. J. Biol. Chem. 270:8559–65. 
82.  Robbins J, Dilworth SM, Laskey RA, Dingwall C. 1991. Two interdependent basic 
domains in nucleoplasmin nuclear targeting sequence: Identification of a class of 
bipartite nuclear targeting sequence. Cell 64:615–623. 
83.  Harel A, Forbes DJ, Hall P. 2004. Importin Beta  : Conducting a Much Larger 
Cellular Symphony. Mol. Cell 16:319–330. 
116 
 
84.  Delmar V a, Chan RC, Forbes DJ. 2008. Xenopus importin beta validates human 
importin beta as a cell cycle negative regulator. BMC Cell Biol. 9:1–11. 
85.  Ciciarello M, Mangiacasale R, Thibier C, Guarguaglini G, Marchetti E, Di Fiore 
B, Lavia P. 2004. Importin β is transported to spindle poles during mitosis and 
regulates Ran-dependent spindle assembly factors in mammalian cells. J. Cell Sci. 
117:6511–22. 
86.  Gruss OJ, Carazo-Salas RE, Schatz C a, Guarguaglini G, Kast J, Wilm M, Le Bot 
N, Vernos I, Karsenti E, Mattaj IW. 2001. Ran induces spindle assembly by 
reversing the inhibitory effect of importin alpha on TPX2 activity. Cell 104:83–93. 
87.  Harel A, Chan RC, Lachish-zalait A, Zimmerman E, Elbaum M, Forbes DJ. 
2003. Importin β Negatively Regulates Nuclear Membrane Fusion and Nuclear Pore 
Complex Assembly. Mol. Biol. Cell 14:4387–4396. 
88.  Ryan KJ, Zhou Y, Wente SR. 2007. The Karyopherin Kap95 Regulates Nuclear Pore 
Complex Assembly into Intact Nuclear Envelopes In Vivo. Mol. Biol. Cell 18:886–
898. 
89.  Conti E, Müller CW, Stewart M. 2006. Karyopherin flexibility in nucleocytoplasmic 
transport. Curr. Opin. Struct. Biol. 16:237–44. 
90.  Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, Julias JG, Vandegraaff N, 
Baumann JG, Wang R, Yuen W, Takemura T, Shelton K, Taniuchi I, Li Y, 
Sodroski J, Littman DR, Coffin JM, Hughes SH, Unutmaz D, Engelman A, 
KewalRamani VN. 2010. Flexible use of nuclear import pathways by HIV-1. Cell 
Host Microbe 7:221–33. 
117 
 
91.  Fassati A, Görlich D, Harrison I, Zaytseva L, Mingot J-M. 2003. Nuclear import of 
HIV-1 intracellular reverse transcription complexes is mediated by importin 7. EMBO 
J. 22:3675–85. 
92.  Ao Z, Huang G, Yao H, Xu Z, Labine M, Cochrane AW, Yao X. 2007. Interaction 
of Human Immunodeficiency Virus Type 1 Integrase with Cellular Nuclear Import 
Receptor Importin 7 and Its Impact on Viral Replication. J. Biol. Chem. 282:13456–
67. 
93.  Busschots K, Voet A, De Maeyer M, Rain J-C, Emiliani S, Benarous R, Desender 
L, Debyser Z, Christ F. 2007. Identification of the LEDGF/p75 Binding Site in HIV-
1 Integrase. J. Mol. Biol. 365:1480–92. 
94.  Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, Debyser Z, 
Engelborghs Y. 2003. LEDGF/p75 is Essential for Nuclear and Chromosomal 
Targeting of HIV-1 Integrase in Human Cells. J. Biol. Chem. 278:33528–39. 
95.  Levin A, Hayouka Z, Friedler A, Loyter A. 2010. Transportin 3 and importin α are 
required for effective nuclear import of HIV-1 integrase in virus-infected cells. 
Nucleus 1:422–31. 
96.  Merle E, Rose RC, LeRoux L, Moroianu J. 1999. Nuclear Import of HPV11 L1 
Capsid Protein is Mediated by Karyopherin α2β1 Heterodimers. J. Cell. Biochem. 
74:628–37. 
97.  Efthymiadis A, Briggs LJ, Jans DA. 1998. The HIV-1 Tat Nuclear Localization 
Sequence Confers Novel Nuclear Import Properties. J. Biol. Chem. 273:1623–1628. 
118 
 
98.  Calnan BJ, Biancalana S, Hudson D, Frankel AD. 1991. Analysis of arginine-rich 
peptides from the HIV Tat protein reveals unusual features of RNA-protein 
recognition. Genes Dev. 5:201–210. 
99.  Cardarelli F, Serresi M, Albanese A, Bizzarri R, Beltram F. 2011. Quantitative 
Analysis of Tat Peptide Binding to Import Carriers Reveals Unconventional Nuclear 
Transport Properties. J. Biol. Chem. 286:12292–9. 
100.  Woods E, Gu L, Mccormick R, Hall WW, Gautier VW. 2013. Novel evidence for 
the nucleocytoplasmic shuttling of HIV-1 Tat by Importin 13. Retrovirology 10:P102. 
101.  Armon-Omer A, Graessmann A, Loyter A. 2004. A Synthetic Peptide Bearing the 
HIV-1 Integrase 161-173 Amino Acid Residues Mediates Active Nuclear Import and 
Binding to Importin α: Characterization of a Functional Nuclear Localization Signal. J. 
Mol. Biol. 336:1117–28. 
102.  Gallay P, Swingler S, Song J, Bushman F, Trono D. 1995. HIV Nuclear Import is 
Governed by the Phosphotyrosine-Mediated Binding of Matrix to the Core Domain of 
Integrase. Cell 83:569–76. 
103.  Petit C, Schwartz O, Mammano F. 2000. The Karyophilic Properties of Human 
Immunodeficiency Virus Type 1 Integrase Are Not Required for Nuclear Import of 
Proviral DNA. J. Virol. 74:7119–7126. 
104.  Ao Z, Fowke KR, Cohen E a, Yao X. 2005. Contribution of the C-terminal tri-lysine 
regions of human immunodeficiency virus type 1 integrase for efficient reverse 
transcription and viral DNA nuclear import. Retrovirology 2:1–15. 
119 
 
105.  Karni O, Friedler a, Zakai N, Gilon C, Loyter a. 1998. A peptide derived from the 
N-terminal region of HIV-1 Vpr promotes nuclear import in permeabilized cells: 
elucidation of the NLS region of the Vpr. FEBS Lett. 429:421–5. 
106.  Agostini I, Popov S, Li J, Dubrovsky L, Hao T, Bukrinsky M. 2000. Heat-Shock 
Protein 70 Can Replace Viral Protein R of HIV-1 during Nuclear Import of the Viral 
Preintegration Complex. Exp. Cell Res. 259:398–403. 
107.  Kappes JC, Wu X. 2004. “Cell-based Method and Assay for Measuring the 
Infectivity and Drug Sensitivity of Immuno-deficiency Virus.” 
108.  Frankel AD, Pabo CO. 1988. Cellular uptake of the tat protein from human 
immunodeficiency virus. Cell 55:1189–1193. 
109.  Pluymers W, Cherepanov P, Schols D, De Clercq E, Debyser Z. 1999. Nuclear 
Localization of Human Immunodeficiency Virus Type 1 Integrase Expressed as a 
Fusion Protein with Green Fluorescent Protein. Virology 258:327–32. 
110.  Schaeffer E, Geleziunas R, Warner C, Greene WC. 2001. Human 
Immunodeficiency Virus Type 1 Nef Functions at the Level of Virus Entry by 
Enhancing Cytoplasmic Delivery of Virions. J. Virol. 75:2993–3000. 
111.  Timmerman LA, Clipstone NA, Ho SN, Northrop JP, Crabtree GR. 1996. Rapid 
shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression. Nature 
383:837–840. 
112.  Crabtree GR, Olson EN. 2002. NFAT Signaling: Choreographing the Social Lives of 
Cells. Cell 109:S67–S79. 
120 
 
113.  Beals CR, Clipstone N a, Ho SN, Crabtree GR. 1997. Nuclear localization of NF-
ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. 
Genes Dev. 11:824–834. 
114.  Torgerson TR, Colosia a D, Donahue JP, Lin YZ, Hawiger J. 1998. Regulation of 
NF-κB, AP-1, NFAT, and STAT1 Nuclear Import in T Lymphocytes by Noninvasive 
Delivery of Peptide Carrying the Nuclear Localization Sequence of NF-kappa B p50. 
J. Immunol. 161:6084–92. 
115.  Dingwall C, Ernberg I, Gait MJ, Green SM, Heaphy S, Karn J, Lowe AD, Singh 
M, Skinner MA, Valeriot R. 1989. Human immunodeficiency virus 1 tat protein 
binds trans-activation-responsive region (TAR) RNA in vitro. Proc. Natl. Acad. Sci. U. 
S. A. 86:6925–6929. 
116.  Tan R, Frankel a D. 1995. Structural variety of arginine-rich RNA-binding peptides. 
Proc. Natl. Acad. Sci. U. S. A. 92:5282–6. 
117.  Schulze-Gahmen U, Upton H, Birnberg A, Bao K, Chou S, Krogan NJ, Zhou Q, 
Alber T. 2013. The AFF4 scaffold binds human P-TEFb adjacent to HIV Tat. Elife 
2:1–14. 
118.  Levine M. 2011. Paused RNA polymerase II as a Developmental Checkpoint. Cell 
145:502–11. 
119.  Kessler M, Mathews MB. 1991. Tat transactivation of the human immunodeficiency 
virus type 1 promoter is influenced by basal promoter activity and the simian virus 40 
origin of DNA replication. Proc. Natl. Acad. Sci. U. S. A. 88:10018–22. 
121 
 
120.  Cardarelli F, Serresi M, Bizzarri R, Beltram F. 2008. Tuning the Transport 
Properties of HIV-1 Tat Arginine-Rich Motif in Living Cells. Traffic 9:528–539. 
121.  Arnold M, Nath A, Hauber J, Kehlenbach RH. 2006. Multiple Importins Function 
as Nuclear Transport Receptors for the Rev Protein of Human Immunodeficiency 
Virus Type 1. J. Biol. Chem. 281:20883–90. 
122.  Mortimer I, Tam P, MacLachlan I, Graham RW, Saravolac EG, Joshi PB. 1999. 
Cationic lipid-mediated transfection of cells in culture requires mitotic activity. Gene 
Ther. 6:403–11. 
123.  Angus L, van der Watt PJ, Leaner VD. 2014. Inhibition of the nuclear transporter, 
Kpnβ1, results in prolonged mitotic arrest and activation of the intrinsic apoptotic 
pathway in cervical cancer cells. Carcinogenesis. 
124.  Stauber RH, Pavlakis GN. 1998. Intracellular trafficking and interactions of the HIV-
1 Tat protein. Virology 252:126–36. 
125.  Dang C V, Lee WMF. 1989. Nuclear and Nucleolar Targeting Sequences of c-erb-A , 
c-myb , N-myc , p53 , HSP70, and HIV tat Proteins. J. Biol. Chem. 264:18019–18023. 
126.  Cardarelli F, Serresi M, Albanese A, Bizzarri R, Beltram F. 2011. Quantitative 
analysis of Tat peptide binding to import carriers reveals unconventional nuclear 
transport properties. J. Biol. Chem. 286:12292–9. 
127.  Miller MD, Farnet CM, Bushman FD. 1997. Human Immunodeficiency Virus Type 




128.  Fassati A. 2006. HIV infection of non-dividing cells: a divisive problem. 
Retrovirology 3:1–15. 
129.  Bukrinsky M. 2004. A Hard Way to the Nucleus. Mol. Med. 10:1–5. 
130.  Depienne C, Mousnier a, Leh H, Le Rouzic E, Dormont D, Benichou S, 
Dargemont C. 2001. Characterization of the nuclear import pathway for HIV-1 
integrase. J. Biol. Chem. 276:18102–7. 
131.  Hearps AC, Jans D a. 2006. HIV-1 integrase is capable of targeting DNA to the 
nucleus via an importin alpha/beta-dependent mechanism. Biochem. J. 398:475–84. 
132.  Nitahara-kasahara Y, Kamata M, Zhang X, Miyamoto Y, Iijima S, Yoneda Y, 
Aida Y, Yamamoto T, Muneta K, Tsunetsugu-yokota Y. 2007. Novel Nuclear 
Import of Vpr Promoted by Importin α Is Crucial for Human Immunodeficiency Virus 
Type 1 Replication in Macrophages. J. Virol. 81:5284–5293. 
133.  Mulder LC, Muesing M a. 2000. Degradation of HIV-1 integrase by the N-end rule 
pathway. J. Biol. Chem. 275:29749–53. 
134.  Kohl NE, Emini E a, Schleif W a, Davis LJ, Heimbach JC, Dixon R a, Scolnick 
EM, Sigal IS. 1988. Active human immunodeficiency virus protease is required for 
viral infectivity. Proc. Natl. Acad. Sci. U. S. A. 85:4686–90. 
135.  Debouck C, Gorniak JG, Strickler JE, Meek TD, Metcalf BW, Rosenberg M. 
1987. Human immunodeficiency virus protease expressed in Escherichia coli exhibits 
autoprocessing and specific maturation of the gag precursor. Proc. Natl. Acad. Sci. U. 
S. A. 84:8903–6. 
123 
 
136.  Lu Y, Spearman P, Ratner LEE. 1993. Human immunodeficiency virus type 1 viral 
protein R localization in infected cells and virions. J. Virol. 67:6542–6550. 
137.  Marzio P Di, Choe S, Ebright M, Knoblauch R, Landau NR, Marzio PDI, Choe S, 
Ebright M, Knoblauch R. 1995. Mutational analysis of cell cycle arrest , nuclear 
localization and virion packaging of human immunodeficiency virus type 1 Vpr . J. 
Virol. 69:7909–7916. 
138.  Mahalingam S, Collman RG, Patel M, Monken CE, Srinivasan A. 1995. 
Functional Analysis of HIV-1 Vpr: Identification of Determinants Essential for 
Subcellular Localization. Virology 212:331–339. 
139.  Zhao L-J, Mukherjee S, Narayan O. 1994. Biochemical Mechanism of HIV-I Vpr 
Function. J. Biol. Chem. 269:15577–15582. 
140.  Pemberton LF, Rosenblum JS, Blobel G. 1999. Nuclear Import of the TATA-
binding Protein  : Mediation by the Karyopherin Kap114p and a Possible Mechanism 
for Intranuclear Targeting. J. Cell Biol. 145:1407–1417. 
141.  Jäkel S, Albig W, Kutay U, Bischoff FR, Schwamborn K, Doenecke D, Görlich D. 
1999. The importin β/importin 7 heterodimer is a functional nuclear import receptor 
for histone H1. EMBO J. 18:2411–2423. 
142.  Mühlhäusser P, Müller EC, Otto a, Kutay U. 2001. Multiple pathways contribute to 
nuclear import of core histones. EMBO Rep. 2:690–6. 
124 
 
143.  Kim BJ, Lee H. 2006. Importin-beta mediates Cdc7 nuclear import by binding to the 
kinase insert II domain, which can be antagonized by importin-α. J. Biol. Chem. 
281:12041–9. 
144.  Rouzic E Le, Benichou S. 2005. The Vpr protein from HIV-1  : distinct roles along the 
viral life cycle. Access 14:1–14. 
145.  Waldhuber MG, Bateson M, Tan J, Greenway AL, McPhee D a. 2003. Studies 
with GFP-Vpr fusion proteins: induction of apoptosis but ablation of cell-cycle arrest 
despite nuclear membrane or nuclear localization. Virology 313:91–104. 
146.  Lu Y, Spearman P, Ratner LEE. 1993. Human immunodeficiency virus type 1 viral 
protein R localization in infected cells and virions. J. Virol. 67:6542–6550. 
147.  Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR, Marzio PDI, Choe S, 
Ebright M, Knoblauch R. 1995. Mutational analysis of cell cycle arrest , nuclear 
localization and virion packaging of human immunodeficiency virus type 1 Vpr . J. 
Virol. 69:7909–7916. 
148.  Yao X, Subbramanian RA, Rougeau N. 1995. Mutagenic analysis of human 
immunodeficiency virus type 1 Vpr  : role of a predicted N-terminal alpha-helical 
structure in Vpr nuclear localization and virion incorporation. J. Virol. 69:7032–7044. 
149.  Heinzinger NK, Bukinsky MI, Haggerty S a, Ragland a M, Kewalramani V, Lee 
M a, Gendelman HE, Ratner L, Stevenson M, Emerman M. 1994. The Vpr protein 
of human immunodeficiency virus type 1 influences nuclear localization of viral 
nucleic acids in nondividing host cells. Proc. Natl. Acad. Sci. U. S. A. 91:7311–5. 
125 
 
150.  Jenkins Y, Mcentee M, Weis K, Greene WC. 1998. Characterization of HIV-1 Vpr 
Nuclear Import: Analysis of Signals and Pathways. J. Cell Biol. 143:875–885. 
151.  Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, Engelborghs 
Y, De Clercq E, Debyser Z. 2003. HIV-1 integrase forms stable tetramers and 
associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 278:372–381. 
152.  Ellison V, Gerton J, Vincent KA, Brown PO. 1995. An Essential Interaction 
between Distinct Domains of HIV-1 Integrase Mediates Assembly of the Active 
Multimer. J. Biol. Chem. 270:3320–3326. 
153.  Bouyac-Bertoia M, Dvorin JD, Fouchier R a, Jenkins Y, Meyer BE, Wu LI, 
Emerman M, Malim MH. 2001. HIV-1 infection requires a functional integrase NLS. 
Mol. Cell 7:1025–35. 
154.  Suzuki Y, Craigie R. 2007. The road to chromatin - nuclear entry of retroviruses. Nat. 
Rev. Microbiol. 5:187–96. 
155.  Levin A, Armon-omer A, Rosenbluh J, Melamed- N, Graessmann A, Waigmann 
E, Loyter A. 2009. Inhibition of HIV-1 integrase nuclear import and replication by a 
peptide bearing integrase putative nuclear localization signal. Retrovirology 6:1–16. 
156.  Depienne C, Mousnier a, Leh H, Le Rouzic E, Dormont D, Benichou S, 
Dargemont C. 2001. Characterization of the nuclear import pathway for HIV-1 
integrase. J. Biol. Chem. 276:18102–7. 
126 
 
157.  Zaitseva L, Cherepanov P, Leyens L, Wilson SJ, Rasaiyaah J, Fassati A. 2009. 
HIV-1 exploits importin 7 to maximize nuclear import of its DNA genome. 
Retrovirology 6:1–18. 
158.  Vives E, Brodin P, Lebleu B. 1997. A Truncated HIV-1 Tat Protein Basic Domain 
Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell 
Nucleus. J. Biol. Chem. 272:16010–16017. 
159.  Brooks H, Lebleu B, Vivès E. 2005. Tat peptide-mediated cellular delivery: back to 
basics. Adv. Drug Deliv. Rev. 57:559–77. 
160.  Caly L, Wagstaff KM, Jans D a. 2012. Nuclear trafficking of proteins from RNA 
viruses: potential target for antivirals? Antiviral Res. 95:202–6. 
161.  Van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, 
Birrer MJ, Leaner VD. 2009. The Karyopherin proteins, Crm1 and Karyopherin β1, 
are overexpressed in cervical cancer and are critical for cancer cell survival and 
proliferation. Int. J. cancer 124:1829–1840. 
162.  WHO. 2013. Global Update of HIV Treatment 2013: Results, Impact and 
Opportunities. 
163.  Strom A-C, Weis K. 2001. Importin-β-like nuclear transport receptors. Genome Biol. 
2:1–9. 
164.  Stewart M. 2007. Molecular mechanism of the nuclear protein import cycle. Nat. Rev. 
Mol. Cell Biol. 8:195–208.  
 
